Document:

AMENDED AND RESTATED LICENSE AGREEMENT BETWEEN THE REGISTRANT AND QIAGEN

 Exhibit 10.25 
  
 AMENDED AND RESTATED LICENSE AGREEMENT 
  
 BY AND BETWEEN COLEY AND QIAGEN 
  
 This Agreement is made and entered into effective as of February 1, 2003 (the “Effective Date”) by and between
Coley Pharmaceutical Group, Inc., a Delaware corporation (hereinafter “COLEY”) having an address of 93 Worcester Road, Suite 101, Wellesley, Massachusetts 02481, USA and QIAGEN GmbH, a German corporation (hereinafter “QIAGEN”),
having an address of QIAGEN-Strasse 1, 40724 Hilden, Germany. 
  
 WHEREAS, COLEY is the owner or exclusive licensee of certain inventions which it wishes to license to QIAGEN; 
  
 WHEREAS, QIAGEN wishes to obtain such a license in accordance with the terms of this Agreement; 
  
 WHEREAS COLEY and QIAGEN have entered into a Sublicense Agreement dated
January 5, 1998, and have agreed on June 30, 2000 to an Amendment to the Sublicense Agreement; and 
  
 WHEREAS COLEY and QIAGEN now wish to amend and restate the Sublicense Agreement in its entirety with this Agreement. 
  
 NOW, THEREFORE, in consideration of the foregoing premises, the Parties agree
as follows: 
  
 ARTICLE 1 DEFINITIONS 
  
 1.1 ADDITIONAL PRODUCT shall have the meaning set forth in Paragraph 2.1

  
 1.2 AFFILIATE shall mean any company, corporation, or business
in which the entity in question owns or controls at least fifty percent (50%) of the voting stock. 
  
 1.3 AGREEMENT YEAR shall mean the annual period commencing upon an anniversary of the Effective Date. 
  
 1.4 EXCLUDED OLIGONUCLEOTIDE shall mean an OLIGONUCLEOTIDE, the manufacture,
use or sale of which is covered by a PATENT RIGHT, and whose use under this Agreement is to be excluded in accordance with the provisions of Paragraphs 2.1 and 2.4. 
  
 1.5 FIELD shall mean any use of Licensed Products or Licensed Processes in animal and/or veterinary uses including both
those requiring approval by a Regulatory Authority and those which do not require approval by a Regulatory Authority, including but not limited to use in or as animal feed. 
  
 1.6 IMPROVEMENTS shall mean any invention, improvement, know-how, trade secret or discovery. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 1 

 1.7 LICENSED PRODUCTS shall mean any product in the FIELD, the sale, use or manufacture of which would
infringe a pending or issued claim of the PATENT RIGHTS but for the license granted hereunder. 
  
 1.8 LICENSED PROCESSES shall mean the processes claimed in PATENT RIGHTS or some portion thereof. 
  
 1.9 NET SALES shall mean the amount billed or invoiced on sales of LICENSED PRODUCTS less: (a) Customary trade, quantity or cash discounts and
non-affiliated brokers’ or agents’ commissions actually allowed and taken; (b) Amounts repaid or credited by reason of rejection or return; (c) To the extent separately stated on purchase orders, invoices or other documents of sale, taxes
levied on and/or other governmental charges made as to production, sale, transportation, delivery or use and paid by or on behalf of QIAGEN; and/or (d) Shipping and insurance charges. 
  
 In the event that a LICENSED PRODUCT under this Agreement is sold in combination with another active ingredient or component
having independent therapeutic effect or diagnostic utility, then “NET SALES,” for purposes of determining royalty payments on the combination, shall be calculated using one of the following methods: 
  

	 	(e)	By multiplying the NET SALES of the combination by the fraction A/A+B, where A is the gross selling price, during the royalty paying period in question, of the LICENSED PRODUCT sold
separately, and B is the gross selling price, during the royalty period in question, of the other active ingredients or components sold separately; or 

  

	 	(f)	In the event that no such separate sales are made of the LICENSED PRODUCT or any of the active ingredients or components in such combination package during the royalty paying period
in question, NET SALES, for the purposes of determining royalty payments, shall be calculated using the above formula where A is the reasonably estimated commercial value of the LICENSED PRODUCT sold separately and B is the reasonably estimated
commercial value of the other active ingredients or components sold separately. Any such estimates shall be determined using criteria to be mutually agreed upon by the Parties. Such estimates shall be reported to COLEY with the reports to be
provided to COLEY pursuant to Paragraph 4.1 hereof. 

  
 1.10 OLIGONUCLEOTIDE shall mean any CPG motif and any CPG oligonucleotide containing immunomodulatory unmethylated cytosine guanine dinucleotides. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 2 

 1.11 PATENT RIGHTS shall mean the issued U.S. patents and pending U.S. applications listed on Appendix A,
the inventions described and claimed therein, and any continuations, divisionals, continuations-in-part, reexaminations, reissues or extensions thereof to the extent the claims are directed to subject matter specifically described in such issued
patents or pending applications; and any and all foreign patents and patent applications corresponding thereto; which will be automatically incorporated in and added to this Agreement and shall periodically be added to Appendix A attached to this
Agreement and made part thereof. 
  
 1.12 PECURA shall mean the
PECURA division of QIAGEN, as further described in Paragraph 10.2. 
  
 1.13 PRODUCT shall mean an ADDITIONAL PRODUCT or a LICENSED PRODUCT. 
  
 1.14 REGULATORY AUTHORITY shall mean the U.S. or foreign government agency or health authority that regulates and is responsible for the manufacture, marketing, sale, and/or pricing of animal and/or veterinary
products. 
  
 ARTICLE 2 
  
 GRANT 
  
 2.1 COLEY hereby grants to QIAGEN and QIAGEN hereby accepts, subject to the terms and conditions hereof, a worldwide
exclusive license under the PATENT RIGHTS to make and have made, to use and have used, to import and have imported, to offer for sale and have offered for sale, and to sell and have sold the LICENSED PRODUCTS, and to practice the LICENSED PROCESSES
in the FIELD. Such license shall include the right to grant further sublicenses, provided, however, that QIAGEN shall provide COLEY with a copy of any sublicense agreement promptly upon its execution and that any such sublicense agreement must
contain terms that do not diminish any of the legal or financial rights of COLEY hereunder, including but not limited to the indemnification and insurance provided under this Agreement. Notwithstanding the foregoing, QIAGEN shall have no right to
incorporate any OLIGONUCLEOTIDE which is an EXCLUDED OLIGONUCLEOTIDE in any LICENSED PRODUCT without the prior agreement of COLEY, which agreement shall be obtained as provided in Paragraph 2.4. COLEY further grants to QIAGEN, and QIAGEN hereby
accepts subject to the terms and conditions hereof, a worldwide non-exclusive license to make and have made, to use and have used, to import and have imported, to offer for sale and have offered for sale, and to sell and have sold OLIGONUCLEOTIDES
solely for any and all preclinical and research purposes (“ADDITIONAL PRODUCTS”). 
  
 2.2 The term of this Agreement and the exclusive license set forth in Paragraph 2.1 shall be from the Effective Date of this Agreement until the expiration of the last to expire of the PATENT RIGHTS or for a period of
fifteen years, whichever is longer. 
  

			
	 2.3 (a)
	  	During the term of this Agreement, QIAGEN hereby grants to COLEY an exclusive, royalty-free worldwide license, with the right to sublicense, to all IMPROVEMENTS conceived or made during such
teen by employees or consultants of the PECURA division of QIAGEN (or any subsequent PECURA stand-alone entity), and any

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 3 

			
	 	  	patent rights claiming such IMPROVEMENTS including any continuations, divisionals, reexaminations, reissues or extensions of any such patent rights, and any and all foreign patents and patent
applications corresponding thereto, to the extent they relate to in-vivo human healthcare applications or in-vivo human healthcare uses of OLIGONUCLEOTIDES; provided, however, that this provision shall cease to be effective as to further
IMPROVEMENTS upon any assignment of this Agreement by QIAGEN to an entity other than PECURA or by PECURA to any other party. QIAGEN shall promptly disclose all such IMPROVEMENTS to COLEY in witing.
		
	 (b)
	  	During the term of this Agreement, COLEY hereby grants to QIAGEN an exclusive, worldwide license, with the right to sublicense, to all IMPROVEMENTS conceived or made during such term by COLEY
employees or consultants or any other third party working for, on behalf of or under the supervision of, COLEY, and any patent rights claiming such IMPROVEMENTS including any continuations, divisionals, reexaminations, reissues or extensions of any
such patent rights, and any and all foreign patents and patent applications corresponding thereto, to the extent they relate to animal and/or veterinary applications and uses for OLIGONUCLEOTIDES, which license shall be on the terms and conditions
set forth herein; provided, however, that this provision shall cease to be effective as to further IMPROVEMENTS upon any assignment of this Agreement by QIAGEN to an entity other than PECURA. COLEY shall promptly disclose all such IMPROVEMENTS to
QIAGEN in writing.

  
 2.4 Set forth as
Appendix B to this Agreement is a list of EXCLUDED OLIGONUCLEOTIDES, which QIAGEN shall not be permitted to develop or commercialize for use in the FIELD under the licenses granted herein due to COLEY’s interest in developing such
OLIGONUCLEOTIDES for human use. Set forth as Appendix C to this Agreement is a list of PERMITTED OLIGONUCLEOTIDES, which QIAGEN shall be permitted to develop or commercialize for any purpose consistent with the licenses granted herein. At least once
every twelve months after the Effective Date, the Parties shall exchange lists of OLIGONUCLEOTIDES not previously included in Appendix B or Appendix C pursuant to this Paragraph 2.4 and which are of interest to either Party and the Parties shall use
good faith efforts to promptly agree on whether to include such OLIGONUCLEOTIDES in the list of EXCLUDED OLIGONUCLEOTIDES or the list of PERMITTED OLIGONUCLEOTIDES. In the event of any failure of the Parties to reach agreement on which list an
OLIGONUCLEOTIDE should be placed in the course of such discussions, despite good faith efforts, COLEY shall be permitted to designate such OLIGONUCLEOTIDE as an EXCLUDED OLIGONUCLEOTIDE for any commercially reasonable concern. Any OLIGONUCLEOTIDE
which has not been reviewed by the Parties in accordance with the foregoing procedure shall be deemed an EXCLUDED OLIGONUCLEOTIDE until it is reviewed by the Parties and shall thereafter be considered a PERMITTED OLIGONUCLEOTIDE unless designated as
an EXCLUDED OLIGONUCLEOTIDE in conjunction with such review. Unless otherwise agreed by QIAGEN, COLEY shall only 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 4 

 
be permitted to request designation of an OLIGONUCLEOTIDE as an EXCLUDED OLIGONUCLEOTIDE at a point in time following any such review and generation of the
corresponding list of EXCLUDED OLIGONUCLEOTIDES (an “Exclusivity Request”) if an existing or potential COLEY collaborator has requested exclusivity in writing for a particular OLIGONUCLEOTIDE either in the course of bona fide negotiations
between COLEY and such potential collaborator or as permitted by a written agreement between COLEY and such existing collaborator. In the event of an Exclusivity Request, if QIAGEN can also demonstrate that an OLIGONUCLEOTIDE which COLEY desires to
exclude pursuant to such Exclusivity Request is under active development by QIAGEN, a QIAGEN AFFILIATE or QIAGEN sublicensee for use in the FIELD, in no event shall QIAGEN be required to agree to such exclusion without appropriate compensation to
QIAGEN, and if the Parties cannot reach an agreement on such matter within sixty (60) days of written request for resolution by either Party, the matter shall be submitted to arbitration as provided in Paragraph 12.2. For the avoidance of doubt,
subject only to the rights granted to QIAGEN herein, COLEY retains the right to make and have made, use or have used any OLIGONUCLEOTIDE for preclinical, clinical, research and other non-commercial purposes. The Parties agree to cooperate in good
faith and in a timely manner in performing any actions contemplated by this Paragraph 2.4. All information exchanged during the course of discussions conducted pursuant to this Paragraph 2.4 shall be deemed Confidential Information of the disclosing
Party and shall not be disclosed or used by the other Party for any purpose other than as expressly provided herein. 
  
 2.5 Upon expiration of the period of exclusivity of this license, QIAGEN shall receive a fully paid up perpetual license to make and have made, to use and
have used, to import and have imported, to offer for sale and have offered for sale, and to sell and have sold the LICENSED PRODUCTS, and to practice the LICENSED PROCESSES in the FIELD. 
  
 2.6 COLEY hereby grants to QIAGEN the right to extend the license granted in Paragraph 2.1 to an AFFILIATE subject to the
terms and conditions hereof. 
  
 2.7 QIAGEN shall use reasonable
efforts to effect introduction of the LICENSED PRODUCTS into the commercial market as soon as practicable, consistent with sound and reasonable business practices and judgment; and thereafter, until the expiration of this Agreement, QIAGEN shall
endeavor to keep LICENSED PRODUCTS reasonably available to the public. 
  
 2.8 COLEY shall have the right to render this license non-exclusive at any time after three (3) years from the Effective Date if QIAGEN cannot reasonably demonstrate that it is engaged in a research, development, manufacturing, marketing,
or licensing program, as appropriate, directed toward the commercialization of LICENSED PRODUCTS. Any dispute regarding this Paragraph 2.8 shall be resolved by arbitration pursuant to Paragraph 12.2 hereof. 
  
 2.9 All sublicenses granted by QIAGEN hereunder shall include a requirement
that the sublicensee use reasonable efforts to effect introduction of the LICENSED PRODUCTS into the commercial market as soon as practicable, consistent with sound and reasonable business practices and judgment and shall bind the sublicensee to
meet 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 5 

 
QIAGEN’s obligations to COLEY under this Agreement and a copy of relevant provisions of this Agreement shall be attached to such sublicense agreements.
Copies of all sublicense agreements shall be provided to COLEY. 
  
 2.10 All rights reserved to the United States Government and others under Public Law 96-517 and 98-620 shall remain and shall in no way be affected by this Agreement. 
  
 ARTICLE 3 
  
 ROYALTIES & OTHER PAYMENTS 
  

			
	 3.1 (a)
	  	QIAGEN shall pay COLEY within forty-five (45) days after the end of each calendar quarter, during the term of the license of Paragraph 2.1, royalties on NET SALES on a country-by-country
basis of all PRODUCTS sold by QIAGEN and its AFFILIATES as follows:
		
	 	  	[**]% on NET SALES of ADDITIONAL PRODUCTS; and [***]% on NET SALES of LICENSED PRODUCTS.
		
	     (b)
	  	On sales between QIAGEN and its AFFILIATES for resale, the royalty shall be paid on the resale.
		
	     (c)
	  	Notwithstanding the above, in the event that commercialization of any PRODUCT hereunder becomes infeasible or uneconomic because of the overall level of royalties payable thereon to all
Parties including COLEY, the Parties hereto shall in good faith discuss a reduction of the above royalty in order to mitigate such circumstances.

  
 3.2 QIAGEN shall pay
to COLEY the following sums within thirty (30) days of the achievement of the indicated milestones: 
  
 $[*******] payable upon the first commercial sale of each of the first four LICENSED PRODUCTS for veterinary use following Regulatory Approval in the
United States. 
  
 For the avoidance of doubt, sale of any LICENSED PRODUCT for a
new indication or therapeutic use shall be considered a new commercial sale for purposes of this Article 3.2 milestone provision. 
  
 3.3 In the case of further sublicenses, QIAGEN shall pay to COLEY [*******] percent ([**]) of all sublicense issue fees, sublicense maintenance fees and
other fees, and [*******] percent ([**]%) of royalties on NET SALES received from any sublicensee, in each case as consideration for a sublicense of rights granted to QIAGEN hereunder, but excluding equity investments in QIAGEN and any funds
received by QIAGEN for the conduct of research. On sales between QIAGEN and any sublicensee for resale, the royalty shall be paid on the resale. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 6 

 ARTICLE 4 
  

REPORTING & CONFIDENTIALITY 
  
 4.1 QIAGEN shall provide brief written annual reports within sixty (60) days after each anniversary of the Effective Date which shall include but not be
limited to: summaries of progress on research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales during the preceding twelve (12) months as well as plans for the coming year. 
  

			
	 4.2 (a)
	  	Commencing upon the first sale of PRODUCTS, QIAGEN agrees to submit to COLEY within forty-five (45) days after the calendar quarters ending March 31, June 30, September 30, and December 31,
reports setting forth for the preceding three (3) month period at least the following information:
		
	 	  	 i)       the number of PRODUCTS sold by QIAGEN, its AFFILIATES and sublicensees;

		
	 	  	 ii)     total billings for each PRODUCT;

		
	 	  	 iii)    an accounting for all LICENSED PROCESSES used or sold;

		
	 	  	 iv)    deductions applicable to determine the NET SALES thereof;

		
	 	  	 v)      the amount of royalty due thereon;

		
	 	  	and with each such royalty report to pay the amount of royalty due. Such report shall be certified as correct by an officer of QIAGEN and shall include a detailed listing of all deductions
from royalties as specified herein. If no royalties are due to COLEY for any reporting period, the written report shall so state.
		
	     (b)
	  	All payments due hereunder shall be payable in United States dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States (as
reported in the Wall Street Journal) on the last working day of each royalty period. Such payments shall be without deduction of exchange, collection or other charges.
		
	     (c)
	  	All such reports shall be maintained in confidence by COLEY, except as required by law.
		
	     (d)
	  	Late payments shall be subject to an interest charge of [**************] percent ([****]%) per month.
		
	     (e)
	  	Any withholding tax levied by any country on payments to COLEY hereunder shall be borne by COLEY. In the event of any such withholding, QIAGEN shall deliver to COLEY a statement indicating
the amount of tax withheld and the justification therefor. QIAGEN shall use its best efforts to do all things necessary to enable COLEY to

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 7 

			
	 	  	claim exemption from any such tax under any double taxation or similar agreement in force and shall provide to COLEY proper evidence of payments of withholding tax and shall assist COLEY by
obtaining or providing such information as may be necessary for United States foreign tax credit purposes.

  
 4.3 COLEY shall not
disclose the contents of any report provided by QIAGEN hereunder to any third party without the prior written consent of QIAGEN, which consent shall not be unreasonably withheld, except to the extent that disclosure of any such information shall be
required by government agencies. 
  
 ARTICLE 5 

 
 RECORD KEEPING 
  
 QIAGEN shall keep, and shall require its AFFILIATES and sublicensees to keep,
accurate and correct records of PRODUCTS made, used, imported or sold under this Agreement, appropriate to determine the amount of royalties due hereunder to QIAGEN. Such records shall be retained for at least three (3) years following a given
reporting period. They shall be available during normal business hours for inspection at the expense of COLEY by COLEY’s Internal Audit Department or by a Certified Public Accountant selected by COLEY and approved by QIAGEN for the sole purpose
of verifying reports and payments hereunder. Such accountant shall not disclose to COLEY any information other than information relating to accuracy of reports and payments made under this Agreement. In the event that any such inspection shows an
underreporting and underpayment in excess of [****] percent ([*]%) for any twelve (12) month period, then QIAGEN shall pay the cost of such examination as well as any additional sum that would have been payable to COLEY had the QIAGEN reported
correctly, plus interest. 
  
 ARTICLE 6 
  
 FILING, PROSECUTION AND MAINTENANCE OF PATENTS 
  
 6.1 COLEY shall have responsibility for the preparation, filing, prosecution
and maintenance of any and all patent applications and patents included in PATENT RIGHTS. COLEY shall promptly inform QIAGEN regarding all matters directly pertaining to prosecution of PATENT RIGHTS in the FIELD, and shall seek QIAGEN’s counsel
concerning all proposed courses of action affecting the scope of PATENT RIGHTS in the FIELD, including but not limited to in which countries patent prosecution should be obtained and all proposed courses of action in any interference proceedings.
COLEY shall provide QIAGEN sufficient opportunity to comment on any document that COLEY intends to file or to cause to be filed with the relevant intellectual property or patent office relating directly to PATENT RIGHTS in the FIELD. 
  
 6.2 If COLEY elects to no longer pay the expenses of prosecution or
maintenance of a patent application or patent included with PATENT RIGHTS, COLEY shall notify QIAGEN not less than sixty (60) days prior to such action and shall thereby allow QIAGEN to directly assume COLEY’s responsibilities with respect
thereto. Any payments which would have been due COLEY under Article 3 shall not longer be paid by QIAGEN for such PATENT RIGHTS so assumed by QIAGEN. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 8 

 ARTICLE 7 
  

MARKING 
  
 7.1 If a PATENT RIGHT has been or is subsequently issued to COLEY or its licensors covering any feature or features of the PRODUCTS, QIAGEN agrees to mark
each and every package, package insert, product information package or container in which the PRODUCTS are used or sold by or for QIAGEN with marking complying with the provisions of Title 35, U.S. Code, Section 287, if required, or any future
equivalent provisions of the United States relating to the marking of patented devices, or with marking complying with the law of the country where the PRODUCTS are shipped, used or sold. 
  
 ARTICLE 8 
  
 INFRINGEMENT 
  
 8.1 With respect to any PATENT RIGHTS under which QIAGEN is exclusively licensed pursuant to this Agreement, QIAGEN shall, subject to COLEY’s prior
written approval, which approval shall not be unreasonably withheld, have the right to prosecute in its own name and at its own expense any infringement of such patent relating solely to the FIELD. QIAGEN agrees to notify COLEY promptly of each
infringement of such patents of which QIAGEN is or becomes aware. Before QIAGEN commences an action with respect to any infringement in the FIELD of such patents, QIAGEN shall give careful consideration to the views of COLEY in making its decision
whether or not to sue, and shall accede to any reasonable request from COLEY to abstain from any such suit, provided that QIAGEN shall in exchange be granted reasonable relief from its obligations hereunder in light of any such continuing
infringement in the FIELD. 
  
 8.2 If QIAGEN elects to sue for
patent infringement, COLEY agrees to be named as nominal third party plaintiff if necessary to the commencement of any such action, and further agrees to provide any information available to QIAGEN and needed by QIAGEN in prosecuting such action.
QIAGEN shall reimburse COLEY for any costs it incurs as part of an action brought by QIAGEN, irrespective of whether COLEY shall become a co-plaintiff. 
  
 8.3 If QIAGEN elects to commence an action as described above, QIAGEN may reduce, by up to [****] percent ([**]%), the royalty due to COLEY earned under
the patent subject to suit by [****] percent ([**]%) of the amount of the expenses and costs of such action, including attorney fees. In the event that such [****] percent ([**]%) of such expenses and costs exceed the amount of royalties withheld by
QIAGEN for any calendar year, QIAGEN may to that extent reduce the royalties due to COLEY from QIAGEN in succeeding calendar years, but never by more than [****] percent [**]%) of the royalty otherwise due in any one year. 
  
 8.4 No settlement, consent judgment or other voluntary final disposition of
the suit may be entered into without the consent of COLEY, which consent shall not be unreasonably withheld. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 9 

 8.5 Recoveries or reimbursements from such action shall first be applied to reimburse QIAGEN for
litigation costs not paid from royalties and then to reimburse COLEY for royalties withheld. Any remaining recoveries or reimbursements shall be retained by QIAGEN. 
  
 8.6 In the event that QIAGEN elects not to exercise its right to prosecute an infringement in the FIELD of the PATENT RIGHTS
pursuant to the above paragraphs, COLEY may do so at its own expense, controlling such action and retaining all recoveries therefrom. 
  
 8.7 If a declaratory judgment action alleging invalidity of any of the PATENT RIGHTS shall be brought against QIAGEN or COLEY, then COLEY, at its sole
option, shall have the right to intervene and take over the sole defense of the action at its own expense. 
  
 8.8 COLEY shall have no obligation to defend any action for infringement brought against QIAGEN by a third party. In the event QIAGEN is sued by a third
party, and as a result of the settlement of such suit is required to pay a royalty to a third party on a LICENSED PRODUCT due to any aspect of the LICENSED PRODUCT which is also covered by the PATENT RIGHTS, the amount of royalty paid will be
deducted from the royalty payment due to COLEY for that LICENSED PRODUCT up to a maximum of [****] percent ([**]%) of the royalty payment otherwise due COLEY. 
  

ARTICLE 9 
  
 TERMINATION OF AGREEMENT 
  
 9.1 Upon any termination of this Agreement, and except as provided herein to the contrary, all rights and obligations of the Parties hereunder shall cease, except as follows: 
  

	 	(a)	COLEY’s right to receive or recover and QIAGEN’s obligation to pay royalties accrued or accruable for payment at the time of any termination; 

  

	 	(b)	QIAGEN’s obligation to maintain records and COLEY’s right to conduct a final audit as provided in Article 5 of this Agreement; and 

  

	 	(c)	Any cause of action or claim of either party, accrued or to accrue because of any breach or default by the other party. 

  
 9.2 In the event QIAGEN fails to make payments due hereunder, COLEY shall
have the right to terminate this Agreement upon forty-five (45) days’ written notice, unless QIAGEN makes such payments plus interest within the forty-five (45) day notice period or unless any such payment is contested in good faith, in which
event COLEY shall not have the right to terminate this Agreement until the matter is resolved and QIAGEN still fails to make any such payment. If payments are not so made, COLEY may immediately terminate this Agreement. 
  
 9.3 In the event that QIAGEN shall be in default in the performance of any
obligations under this Agreement (other than as provided in Paragraph 9.2 above which shall take precedence over any other default), and if the default has not been remedied within ninety (90) days after the date of notice in writing of such
default, COLEY may terminate 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 10 

 
this Agreement immediately by written notice, unless any such obligation is contested in good faith, in which event COLEY shall not have the right to
terminate this Agreement until the matter is resolved and QIAGEN still fails to perform any such obligation. 
  
 9.4 In the event that QIAGEN shall become insolvent, shall make an assignment for the benefit of creditors, or shall have a petition in bankruptcy filed
for or against it, which petition shall remain unstayed for a period of ninety (90) days, COLEY shall have the right to terminate this entire Agreement immediately upon giving QIAGEN written notice of such termination. 
  
 9.5 In the event the license granted to QIAGEN hereunder terminates for any
reason, any further sublicenses granted by QIAGEN under this Agreement shall continue; provided that, such sublicensee agrees in writing that COLEY is entitled to enforce such agreements directly against such sublicensee. 
  
 9.6 QIAGEN shall have the right to terminate this Agreement at any time by
giving ninety (90) days advance written notice to COLEY to that effect. Upon termination, a final report shall be submitted and any royalty payments due to COLEY shall become immediately payable. 
  
 9.7 QIAGEN shall have the right during a period of six (6) months following
the effective date of any termination to sell or otherwise dispose of the PRODUCT existing at the time of such termination, and shall make a final report and payment of all royalties related thereto within sixty (60) days following the end of such
period or the date of the final disposition of such inventory, whichever first occurs. 
  
 ARTICLE 10 
  
 ASSIGNMENT

  
 10.1 The rights and licenses granted by COLEY in this
agreement are specific and, except as provided in Section 10.2, may not be assigned or otherwise transferred to any party other than to an AFFILIATE of QIAGEN without the prior written approval of COLEY, which approval shall not be unreasonably
withheld; provided, however, that QIAGEN, without such approval, may assign subject to Public Law 96-517 and Public Law 98-620, all of its rights hereunder to the acquiring party in connection with the transfer of all or substantially all of its
business and assets to which this agreement relates to an acquiring party or in the event of its merger or consolidation with that acquiring party, if and only if the assignee shall assume all obligations of QIAGEN under this Agreement. Any
attempted assignment or transfer without any such approval, if required, shall be null and void. 
  
 10.2 COLEY and QIAGEN acknowledge that it is QIAGEN’s intent to incorporate as a new corporate entity, PECURA, which is currently operated as a
division of QIAGEN. The newly incorporated PECURA may or may not be an AFFILIATE of QIAGEN. COLEY hereby agrees to approve the assignment of this License Agreement to PECURA provided that PECURA agrees in writing to assume all obligations of QIAGEN
under this Agreement. This Agreement shall be binding upon and inure to the benefit of each party to this Agreement, its AFFILIATES, and its permitted successors and assigns. COLEY and 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 11 

 
QIAGEN shall be responsible for the compliance by its AFFILIATES with the terms and conditions of this Agreement. 
  
 ARTICLE 11 
  
 REPRESENTATIONS AND WARRANTIES: LIMITATIONS 
  
 11.1 Nothing in this agreement shall be construed as: 
  

	 	(a)	A warranty or representation by COLEY as to the validity or scope of any PATENT RIGHT; or 

  

	 	(b)	A warranty or representation that anything made, used or sold under the license granted in this Agreement is or will be free from infringement of patents owned by third parties; or

  

	 	(c)	Conferring a right to use in advertising, publicity or otherwise the name of COLEY, or the inventors, unless COLEY has specifically approved the same in writing.

  
 11.2 COLEY represents that; to the best of its
knowledge, any patents issued in respect of the PATENT RIGHTS will, when issued, be free of any restrictions except for any residual rights held by the U.S. Government under the Federal Patent Policy as a result of previous or present sponsorship.

  
 11.3 COLEY EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED OR EXPRESS
WARRANTIES AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE PATENT RIGHTS, BIOLOGICAL MATERIAL, INFORMATION SUPPLIED BY QIAGEN, LICENSED PROCESSES OR PRODUCTS CONTEMPLATED BY THIS AGREEMENT.
COLEY assumes no responsibilities whatever with respect to design, development manufacture, use, sale or other disposition by QIAGEN or its AFFILIATES of PRODUCTS or LICENSED PROCESSES. The entire risk as to the design, development, manufacture,
offering for sale, sale, or other disposition and performance of PRODUCTS and LICENSED PROCESSES by QIAGEN or its AFFILIATES is assumed by QIAGEN and AFFILIATES. 
  
 ARTICLE 12 
  
 GENERAL 
  

			
	 12.1 (a)
	  	QIAGEN, its AFFILIATES and sublicensees, shall indemnify, defend and hold harmless COLEY its current or former directors, officers, employees, and agents and their respective successors,
heirs and assigns (the “Indemnities”), against any liability, damage, loss or expenses (including reasonable attorneys’ fees and expenses of litigation) incurred by or imposed upon the Indemnities or any one of them in connection with
any claims, suits, actions, demands or judgments arising out any theory of product liability (including, but not limited to, actions in the form of tort, warranty, or strict liability) concerning any product, process or

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 12 

			
	 	  	service made, used or sold by QIAGEN, or its AFFILIATES or sublicensees pursuant to any right or license granted under this Agreement.
		
	     (b)
	  	QIAGEN agrees, at its own expense, to provide attorneys reasonably acceptable to COLEY to defend against any actions brought or filed against any party indemnified hereunder with respect to
the subject of indemnity contained herein, whether or not such actions are rightfully brought.
		
	     (c)
	  	Beginning at the time as any such product, process or service is being commercially distributed or sold (other than for the purpose of obtaining regulatory approvals) by QIAGEN or by a
sublicensee, AFFILIATE or agent of QIAGEN, QIAGEN shall, at its sole cost and expense procure and maintain comprehensive general liability insurance in amounts not less than $[****] per incident and $[*******] annual aggregate and naming the
Indemnitees as additional insureds. During clinical trials of any such product, process or service QIAGEN shall, at its sole cost and expense, procure and maintain comprehensive general liability insurance in such equal or lesser amounts as COLEY
shall require, naming the Indemnitees as additional insureds. Such comprehensive general liability insurance shall provide (i) product liability coverage and (ii) broad form contractual liability coverage for COLEY’s indemnification under this
Agreement. If QIAGEN elects to self-insure all or part of the limits described above (including deductibles or retentions which are in excess of $[******] annual aggregate) such self-insurance program must be acceptable to COLEY. The minimum amounts
of insurance coverage required shall not be construed to create a limit of QIAGEN’s liability with respect to its indemnification under this Agreement.
		
	     (d)
	  	QIAGEN shall provide COLEY with written evidence of such insurance upon request of COLEY. QIAGEN shall provide COLEY with written notice at least fifteen (15) days prior to the cancellation,
non-renewal or material change in such insurance; if QIAGEN does not obtain replacement insurance providing comparable coverage within such fifteen (15) day period, COLEY shall have the right to terminate this Agreement effective at the end of such
fifteen (15) day period without notice or any additional waiting periods.
		
	 	  	 (e)    QIAGEN shall maintain such comprehensive general liability insurance beyond the expiration or termination of
this Agreement during (i) the period that any product, process, or service, relating to, or developed pursuant to, this Agreement is being commercially distributed or sold by QIAGEN or by a sublicensee, AFFILIATE or agent of QIAGEN and (ii) a
reasonable period after the period referred to in (e)(i) above which in no event shall be less than fifteen (15) years.

  
 12.2 In the event of
any controversy or claim arising out of or relating to any provision of this Agreement or the breach thereof, the Parties shall try to settle such conflicts amicably between themselves. Subject to the limitation stated in the final sentence of this
section, any such conflict which the Parties are unable to resolve shall be settled through arbitration conducted in accordance with the rules of the American Arbitration Association. The demand for arbitration shall be filed within a reasonable
time after the controversy or claim has arisen, and in no event after the date upon which institution of legal proceedings 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 13 

 
based on such controversy or claim would be barred by the applicable statutes of limitation. Such arbitration shall be held in London, England, unless
otherwise agreed by the Parties. The award through arbitration shall be final and binding. Either Party may enter any such award in a court having jurisdiction or may make application to such court for judicial acceptance of the award and an order
of enforcement, as the case may be. Notwithstanding the foregoing, either Party may, without recourse to arbitration, assert against the other Party a third-party claim or cross-claim in any action brought by a third party, to which the subject
matter of this Agreement may be relevant. 
  
 12.3 Should a court
of competent jurisdiction later consider any provision of this Agreement to be invalid, illegal, or unenforceable, it shall be considered severed from this Agreement, and it is the intention of the Parties that the remainder of this Agreement shall
not be affected thereby. It is further the intention of the Parties that in lieu of each such provision which is invalid, illegal or unenforceable, there be substituted or added as part of this Agreement a provision which shall be as similar as
possible in economic and business objectives as intended by the Parties, but which shall be valid, legal and enforceable. 
  
 12.4 No waiver by a Party of any breach of this Agreement, no matter how long continuing or how often repeated, shall be deemed a waiver of any subsequent
breach thereof, nor shall any delay or omission on the part of a Party to exercise any right, power or privilege hereunder be deemed a waiver of such right, power or privilege. 
  
 12.5 The relationship between the Parties is that of independent contractor and contractee. QIAGEN shall not be deemed to be
an agent of COLEY in connection with the exercise of any rights hereunder, and shall not have any right or authority to assume or create any obligation or responsibility on behalf of COLEY. 
  
 12.6 No Party hereto shall be deemed to be in default of any provision of
this Agreement, or for any failure in performance, resulting from acts or events beyond the reasonable control of such Party, such acts of God, acts of civil or military authority, civil disturbance, war, strikes, fires, power failures, natural
catastrophes or other “force majeure” events. 
  
 ARTICLE 13 
  
 NOTICES; APPLICABLE LAW

  
 13.1 Any notice, report or payment provided for in this
Agreement shall be deemed sufficiently given if in writing and when sent by express courier, certified or registered mail addressed to the Party for whom intended at the address set forth below, or to such address as either Party may hereafter
designate in writing to the other. 
  

					
	(a)	  	For COLEY:	  	 Coley Pharmaceutical Group, Inc.
 93 Worcester Road,
Suite 101
 Wellesley, Massachusetts 02481 USA
 Attn: Robert
Bratzler, CEO

			
	(b)	  	For QIAGEN:	  	 QIAGEN GmbH
 QIAGEN-Strasse 1
 40724 Hilden
 GERMANY
 Attn: Peer Schatz, Chief Financial Officer

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 14 

 13.2 This Agreement shall be construed, interpreted and applied in accordance with the laws of the
COMMONWEALTH of Massachusetts without regard to its conflict of law rules. 
  
 13.3 QIAGEN agrees to comply with all laws and regulations applicable to the subject matter of this Agreement. In particular; it is understood and acknowledged that the transfer of certain commodities and technical
data is subject to United States laws and regulations controlling the export of such commodities and technical data, including all Export Administration Regulations of the United States Department of Commerce. These laws and regulations among other
things, prohibit or require a license for the export of certain types of technical data to certain specified countries. QIAGEN hereby agrees and gives written assurance that it will comply with all United States laws and regulations controlling the
export of commodities and technical data, that it will be solely responsible for any violation of such by QIAGEN or its AFFILIATES or sublicensees, and that it will defend and hold COLEY harmless in the event of any legal action of any nature
occasioned by such violation. 
  
 ARTICLE 14 
  
 INTEGRATION 
  
 14.1 This Agreement constitutes the final and entire agreement between the
Parties, and supersedes all prior written agreements with respect to the subject matter hereof, and any prior or contemporaneous oral understanding regarding the subject matter hereof. Any representation, promise or condition in connection with such
subject matter which is not incorporated in this Agreement shall not be binding on either party. No modification, renewal, extension or termination of this Agreement or any of its provisions shall be binding upon the party against whom enforcement
of such modification, renewal, extension or termination is sought, unless made in writing and signed on behalf of such Party by a duly authorized officer. 
  
 [Remainder of Page Intentionally Left Blank] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 15 

 IN WITNESS WHEREOF, each of the Parties have caused this Agreement to be executed by its duly authorized
representative. 
  

									
	 Signed as of the 9th day of July, 2003
	 	 	 	 Signed as of the 11th day of July, 2003

			
	LICENSOR	 	 	 	LICENSEE
	 COLEY PHARMACEUTICAL GROUP, Inc.
	 	 	 	 QIAGEN GmbH

					
	 By:
	 	 /s/ Robert Bratzler
	 	 	 	 By:
	 	 /s/ Peer Schatz

	 	 	 Robert Bratzler
	 	 	 	 	 	 Peer Schatz

	 	 	 CEO
	 	 	 	 	 	 Chief Financial Officer

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 16 

  
 Appendix A List of Patent
Rights 
 APPENDIX A 
 License Rights 
  
 UNIVERSITY OF IOWA RESEARCH
FOUNDATION 
  

																	
	WG&S ID

	 	UIRF ID

	 	MISC 1D

	 	SN

	 	FILING
DATE

	 	INVENTORS

	 	ASSIGNEES

	 	TITLE

	 	STATUS

	[*********]	 	[*********]
[*********]	 	 	 	[*********]	 	[*********]
[*********]	 	 	 	 	 	[*********]
[*********]	 	Issued US 6,194,388
B1 02-27-2001
									
	[*********]  
	 	[*******]	 	 	 	[*********]  
	 	[*********]  
	 	[*********]  
	 	[*********]  
	 	[*********]  
	 	Granted Patent
No. 713040
	[*********]
[*********]
[*********]	 	 	 	 	 	[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]	 	[*********]
[*********]	 	[*********]	 	Pending
Pending
Pending
									
	[*********]	 	[********]]	 	 	 	[*********]	 	[*********]
[*********]	 	 	 	 	 	[*********]
[*********]	 	Issued 6,207,646
B1 03-27-2001
									
	[*********]	 	[*********]	 	 	 	[*********]
[*********]	 	[*********]	 	 	 	 	 	[*********]
[*********]	 	Issued US 6,239,116
B1 05-29-2001
									
	[*********]	 	[*********]	 	 	 	[*********]  
	 	[*********]	 	[*********]  
	 	 	 	[*********]  
	 	Abandoned, Divisional
Filed
	[*********]
[*********]
[*********]
[*********]
[*********]	 	[*********]
[*********]	 	 	 	[*********]
[*********]
[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]
[*********]	 	 	 	[*********]	 	Pending
Pending
Pending
Pending
Allowed 335397-
03/08/01
	[*********]
[*********]	 	 	 	 	 	[*********]
[*********]	 	[*********]
[*********]	 	 	 	 	 	 	 	Allowed 12/06/00
Pending
									
	[*********]
[*********]
[*********]
[*********]	 	[********]	 	 	 	[*********]
[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	Accepted (753688)
Pending
Pending
Pending
									
	[*********]
[*********]	 	[********]	 	 	 	[*********]
[*********]	 	[*********]
[*********]	 	 	 	 	 	[*********]
[*********]	 	Issued US 6,339,068
B1 01-15-2002
									
	[*********]	 	[*********]	 	 	 	[*********]	 	[*********]	 	[*********]	 	[*********]	 	[*********]	 	Pending
(Expedited Exam)
	[*********]
[*********]	 	[*********]
[*********]	 	 	 	[*********]
[*********]	 	[*********]
[*********]	 	[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]	 	Pending
Pending
									
	[*********]	 	[*********]
[*********]	 	 	 	[*********]	 	[*********]	 	 	 	[*********]
[*********]	 	[*********]
[*********]
[*********]
[*********]	 	Allowed
									
	[*********]	 	 	 	 	 	[*********]	 	[*********]	 	 	 	[*********]
[*********]	 	[*********]
[*********]
[*********]	 	Allowed

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 17 

  
 Appendix A List of Patent
Rights 
  
 UNIVERSITY OF IOWA RESEARCH FOUNDATION

  

																	
	WG&S ID

	 	UIRF ID

	 	MISC ID

	 	SN

	 	 FILING
 DATE

	 	INVENTORS

	 	ASSIGNEES

	 	TITLE

	 	STATUS

	[*********]	 	 	 	 	 	[*********]	 	[*********]	 	[*********]	 	[*********]	 	 	 	Pending
									
	[*********]	 	 	 	 	 	[*********]	 	[*********]	 	 	 	 	 	 	 	Pending
									
	[*********]	 	 	 	 	 	[*********]	 	 	 	 	 	 	 	 	 	Issued 6,406,705 B1
06-18-2002
									
	[*********]	 	[*********]	 	 	 	[*********]	 	 	 	 	 	 	 	 	 	Issued 6,218,371 B1
04-17-2001
									
	[*********]	 	[*********]	 	 	 	[*********]
[*********]	 	 	 	 	 	 	 	 	 	Entered National Stage
Published 10/14/99
									
	[*********]
[*********]
[*********]
[*********]
[*********]	 	[*********]	 	 	 	[*********]
[*********]
[*********]
[*********]
[*********]	 	[*********]	 	 	 	 	 	 	 	Pending
Pending
Published 01/17/01 EP 1067956
Pending
Pending
									
	[*********]	 	[*********]	 	 	 	[*********]	 	[*********]	 	[*********]	 	[*********]	 	[*********]	 	Pending
(Non-provisional
of 7030, 7031
and 7040)

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 18 

  
 Appendix A List of Patent
Rights 
  
 UNIVERSITY OF IOWA RESEARCH FOUNDATION

  

																	
	WG&S ID

	 	UIRF ID

	 	MISC ID

	 	SN

	 	 FILING
 DATE

	 	INVENTORS

	 	ASSIGNEES

	 	TITLE

	 	STATUS

	[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]	 	[*********]	 	 	 	  
 [*********]
[*********]
[*********]
[*********]
[*********]
  
 [*********]
[*********]
[*********]
[*********]
[*********]
  
 [*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
	 	 	 	  
 [*********]
[*********]
	 	  
 [*********]
[*********]
	 	[*********]
[*********]	 	Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending - Published
Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
Granted
Pending
Pending
Pending
Pending
Pending
									
	[*********]	 	[*******]	 	 	 	[*********]	 	[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]
[*********]	 	Pending
Office Action due [**]
									
	[*********]	 	[*******]	 	 	 	[*********]	 	[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	Pending
									
	[*********]	 	[*******]	 	 	 	[*********]	 	[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]	 	Accepted
No. 754463, Issued
3/6/03
									
	[*********]	 	[********]
[*******]	 	 	 	[*********]	 	[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	Pending
Divisional of
C1039/7005
									
	[*********]	 	[*********]	 	 	 	[*********]	 	[*********]	 	[*********]	 	[*********]	 	[*********]	 	Pending
	 	 	[******]	 	 	 	 	 	 	 	[*********]
[*********]	 	[*********]
[*********]	 	[*********]
[*********]	 	Divisional of
C1039/7005
									
	[*********]	 	[******]	 	 	 	[*********]	 	[*********]	 	[*********]	 	[*********]	 	[*********]	 	Pending
	 	 	[*******]
[*********]	 	 	 	 	 	 	 	[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	[*********]	 	Divisional of
C1039/7004

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 19 

  
 Appendix A List of Patent
Rights 
  
 UNIVERSITY OF IOWA RESEARCH FOUNDATION

  

																	
	 WG&S ID

	 	UIRF ID

	 	MISC ID

	 	SN

	 	 	 	INVENTORS

	 	ASSIGNEES

	 	TITLE

	 	 STATUS

									
	 [*************]
	 	[****]	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[**********
*********]	 	 Pending
 (Divisional of C1039/7026)

									
	 [*************]
	 	[****]	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[********
******]	 	Pending
									
	 [****]
 [****]
 [****]
 [****]
	 	 	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[********
******]	 	 
									
	 [*************]
	 	[****]	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[*******]	 	 Pending
 Divisional of C1039/7001EP

									
	 [*************]
	 	[****]	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[*******]	 	Pending
									
	 [*************]
	 	[****]	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[*******]	 	 Pending
 Divisional of C1039/7001EP

									
	 [*************]
	 	[****]	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[*******]	 	Pending
									
	 [*************]
	 	[****]	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[*******]	 	 Pending
 Divisional of C1039/7001EP

									
	 [*************]
	 	[****]	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[*******]	 	 Pending
 Divisional of C1039/7001EP

									
	 [*************]
	 	[****]	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[*******]	 	 Pending
 Divisional of C1039/7009

									
	 [*************]
	 	 	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[********
******]	 	 Pending
 Divisional of C1039/7025

									
	 [*************]
	 	[****]	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[*******]	 	 Pending
 Divisional of C1039/7005AU

									
	 [*************]
	 	[****]	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[*******]	 	 Pending; Non-provisional of
 C1039/7047 and C1039/7064

									
	 [*************]
	 	[****]	 	 	 	[*************]	 	[****]	 	[******]	 	[*****]	 	[*******]	 	Pending

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 20 

  
 Appendix A List of Patent
Rights 
  
 OTTAWA HEALTH RESEARCH INSTITUTE 

 

																	
	WG&S ID

	 	UIRF ID

	 	MISC ID

	 	SN

	 	 FILING
 DATE

	 	INVENTORS

	 	ASSIGNEES

	 	TITLE

	 	STATUS

	[*********]	 	 	 	 	 	[*********]	 	[*********]	 	[*********]
[*********]	 	[*********]
[*********]	 	[*********]
[*********]	 	Pending
	[*********]	 	 	 	 	 	[*********]	 	[*********]	 	[*********]	 	[*********]	 	[*********]	 	Pending
	[*********]	 	 	 	 	 	[*********]	 	 	 	[*********]	 	[*********]	 	[*********]	 	Pending
	[*********]	 	 	 	 	 	[*********]	 	 	 	 	 	 	 	 	 	Pending
	[*********]	 	 	 	 	 	[*********]	 	 	 	 	 	 	 	 	 	Pending
	[*********]	 	 	 	 	 	[*********]	 	 	 	 	 	 	 	 	 	Pending
	[*********]	 	 	 	 	 	[*********]	 	 	 	 	 	 	 	 	 	Pending -laid
open as
2002-516294
	[*********]	 	 	 	 	 	[*********]	 	 	 	 	 	 	 	 	 	Pending
	[*********]	 	 	 	 	 	[*********]	 	 	 	 	 	 	 	 	 	Pending

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 21 

  

															
	 Appendix A List of patent Rights
  
 COLEY PHARMACEUTICAL GmbH
  

	WG&S ID

	 	MISC ID

	 	SN

	 	 	 	INVENTORS

	 	ASSIGNEES

	 	TITLE

	 	STATUS

	[*********]	 	 	 	[*********]	 	[*********]	 	[*********]
[*********]	 	[*********]
[*********]	 	[*********]
[*********]
[*********]
[*********]	 	Pending
								
	[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]	 	 	 	[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]	 	[*********]	 	[*********]
[*********]	 	[*********]
[*********]	 	[*********]
[*********]
[*********]	 	Pending
Pending
Pending
Pending
Pending - laid open
as 2002- 514397
Pending
								
	[*********]	 	 	 	[*********]	 	[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	Pending
								
	[*********]
[*********]
[*********]
[*********]
[*********]	 	 	 	[*********]	 	[*********]	 	[*********]
[*********]
[*********]	 	 	 	[*********]
[*********]
[*********]	 	Pending
								
	[*********]	 	 	 	[*********]	 	[*********]	 	[*********]
[*********]
[*********]
[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]
[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	Pending (Provisional)
								
	[*********]	 	 	 	[*********]	 	[*********]	 	[*********]
[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]
[*********]	 	[*********]
[*********]	 	Pending (Provisional)
								
	[*********]	 	 	 	[*********]	 	[*********]	 	[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]
[*********]
[*********]
[*********]
[*********]	 	[*********]
[*********]
[*********]	 	Pending (Provisional)
								
	[*********]	 	 	 	[*********]	 	[*********]	 	[*********]
[*********]	 	[*********]
[*********]	 	[*********]
[*********]
[*********]
[*********]	 	Continuation of C1041/7002
								
	[*********]	 	 	 	 	 	[*********]	 	[*********]
[*********]
[*********]	 	[*********]	 	[*********]
[*********]	 	In progress-to be filed July 17,
2003 off of
provisional
C1041/7028
								
	[*********]	 	 	 	 	 	[*********]	 	[*********]
[*********]
[*********]	 	[*********]	 	[*********]
[*********]	 	To be filed in correlation with
C1041/7038

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 22 

  
 Appendix A List of Patent
Rights 
  
 COLEY PHARMACEUTICAL GROUP, INC. 

 

															
	W C&S ID

	 	MISC ID

	 	SN

	 	FILING
DATE

	 	INVENTORS

	 	ASSIGNEES

	 	TITLE

	 	STATUS

	[*********]	 	 	 	[*********]	 	[*********]	 	 	 	 	 	 	 	Pending
								
	[*********]
[*********]	 	 	 	[*********]
[*********]	 	[*********]
[*********]	 	 	 	 	 	 	 	Issued US 5,663,153
09-02-97
								
	[*********]
[*********]	 	 	 	[*********]
[*********]	 	[*********]
[*********]	 	 	 	 	 	 	 	Issued US 5,723,335
03-03-98
								
	[*********]	 	 	 	[*********]	 	[*********]	 	 	 	 	 	 	 	Pending

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 23 

  
 APPENDIX B 

 
 EXCLUDED OLIGONUCLEOTIDES 
  
 [****] 
 [****] 
 [****] 
 [****] 
 [****] 
 [****] 
 [****] 
 [****] 
 [****]

 [****] 
 [****] 
 [*********************************************************************************] 
 [*************************] 
 [************************************] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 24 

  
 APPENDIX C 

 
 PERMITTEED OLIGONUCLEOTIDES 
  

							
	CpG-ODN

	 	Sequence

	 	Length

	 	Backbone

	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]
	[****]	 	[****************************]	 	[**]	 	[**]

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  
 25NON-EXCLUSIVE LICENSE AGREEMENT BETWEEN THE REGISTRANT AND CHIRON CORPORATION

 Exhibit 10.27 
  
 COLEY PHARMACEUTICAL GROUP, INC. 
  
 and 
  
 CHIRON CORPORATION 
  

  
 NON-EXCLUSIVE LICENSE AGREEMENT 
  

  
 Dated December 22, 2003 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

 

 Table of Contents 
  

							
	 1.
	  	DEFINITIONS	  	1
	 	  	1.1	  	 General
	  	1
	 2.
	  	LICENSE GRANTS	  	11
	 	  	2.1	  	 License Grant to Licensee
	  	11
	 	  	2.2	  	 Limitations
	  	11
	 	  	2.3	  	 Sublicenses
	  	11
	 	  	2.4	  	 License Grant to Coley
	  	11
	 3.
	  	PAYMENTS AND ROYALTIES	  	12
	 	  	3.1	  	 Up-Front Payment
	  	12
	 	  	3.2	  	 Development Milestone Payments
	  	12
	 	  	3.3	  	 Minimum Annual Payments
	  	13
	 	  	3.4	  	 Royalty Payments
	  	13
	 	  	3.5	  	 Withholding; Payments
	  	15
	 	  	3.6	  	 Late Payments
	  	15
	 	  	3.7	  	 Third Party Licenses
	  	15
	 	  	3.8	  	 Audit of Records
	  	15
	 4.
	  	DEVELOPMENT; DILIGENCE OBLIGATIONS; ADVISORY COMMITTEE	  	16
	 	  	4.1	  	 Diligence Generally
	  	16
	 	  	4.2	  	 Development and Commercialization Plans
	  	16
	 	  	4.3	  	 Collaboration Manager
	  	17
	 	  	4.4	  	 Regulatory Approvals
	  	17
	 	  	4.5	  	 Cooperation by Coley
	  	18
	 5.
	  	TRANSFER AND SUPPLY OF MATERIALS; MARKING	  	18
	 	  	5.1	  	 Transfer of Materials
	  	18
	 	  	5.2	  	 Manufacture of Immune Modulator; Regulatory Filings and Manufacturing Information
	  	19
	 	  	5.3	  	 Marking
	  	22
	 6.
	  	TERM AND TERMINATION	  	22
	 	  	6.1	  	 Term
	  	22
	 	  	6.2	  	 Termination
	  	22
	 	  	6.3	  	 Effects of Expiration or Termination
	  	23
	 7.
	  	CONFIDENTIALITY	  	24
	 	  	7.1	  	 Nondisclosure Obligation
	  	24
	 	  	7.2	  	 Permitted Disclosures
	  	25
	 	  	7.3	  	 Partial Disclosures
	  	25
	 	  	7.4	  	 Publishing
	  	25
	 	  	7.5	  	 Publicity
	  	26
	 8.
	  	MAINTENANCE AND ENFORCEMENT OF PATENT RIGHTS	  	26
	 	  	8.1	  	 Responsibility for Patent Rights
	  	26
	 	  	8.2	  	 Infringement by Third Parties
	  	26
	 	  	8.3	  	 Settlements
	  	27
	 	  	8.4	  	 Infringement Claims
	  	27

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 i 

							
	 	  	8.5	  	 Recoveries and Damages
	  	27
	 	  	8.6	  	 Subject to Iowa Agreement
	  	28
	 9.
	  	REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PARTIES	  	28
	 	  	9.1	  	 Representations and Warranties of Each Party to the Other
	  	28
	 	  	9.2	  	 Covenants of Licensee
	  	28
	 	  	9.3	  	 Representations and Warranties of Coley
	  	29
	 	  	9.4	  	 Bayh-Dole
	  	29
	 10.
	  	INDEMNIFICATION AND LIMITATION OF LIABILITY	  	29
	 	  	10.1	  	 Indemnification by Licensee
	  	29
	 	  	10.2	  	 Indemnification by Coley
	  	30
	 	  	10.3	  	 Indemnification Procedure
	  	30
	 	  	10.4	  	 Settlements
	  	31
	 	  	10.5	  	 Limitation of Liability
	  	31
	 	  	10.6	  	 Insurance
	  	31
	 	  	10.7	  	 Warranty Disclaimer
	  	32
	 11.
	  	REPORTING OF SAFETY AND OTHER DATA	  	32
	 	  	11.1	  	 Safety Data
	  	32
	 	  	11.2	  	 Preclinical and Clinical Data
	  	32
	 	  	11.3	  	 Coley Reports
	  	33
	 12.
	  	MISCELLANEOUS	  	33
	 	  	12.1	  	 Assignment
	  	33
	 	  	12.2	  	 Governing Law
	  	33
	 	  	12.3	  	 Arbitration
	  	33
	 	  	12.4	  	 Injunctive Relief and Jurisdiction
	  	34
	 	  	12.5	  	 Waiver
	  	34
	 	  	12.6	  	 Independent Relationship
	  	34
	 	  	12.7	  	 Export Control
	  	34
	 	  	12.8	  	 Entire Agreement; Amendment
	  	35
	 	  	12.9	  	 Notices
	  	35
	 	  	12.10	  	 Force Majeure
	  	36
	 	  	12.11	  	 Severability
	  	36
	 	  	12.12	  	 Recording
	  	36
	 	  	12.13	  	 Further Actions
	  	37
	 	  	12.14	  	 Counterparts
	  	37
	 	  	12.15	  	 Iowa Agreement
	  	37
				
	 Exhibit
	  	A	  	 Iowa Agreement
	  	 
	 Exhibit
	  	B	  	 Licensee’s Existing IP
	  	 
	 Exhibit
	  	C	  	 Patent Rights
	  	 
	 Exhibit
	  	D	  	 Form of Press Release
	  	 

  
 Portions of this Exhibit were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 ii 

 NON-EXCLUSIVE LICENSE AGREEMENT 
  
 This NON-EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), effective as of December 22, 2003 (the “Effective
Date”), is between Coley Pharmaceutical Group, Inc., a Delaware corporation located at 93 Worcester Street, Suite 101, Wellesley, Massachusetts 02481 (“Coley”), and Chiron Corporation., a Delaware corporation having a
principal place of business at 4560 Horton Street, Emeryville, California 94608 (“Licensee”) (each, a “Party” and collectively, the “Parties”). 
  
 RECITALS 
  
 WHEREAS, Coley is the owner or licensee of certain rights, title, and
interests in, and know-how related to, proprietary technologies involving immunomodulatory oligonucleotides; and 
  
 WHEREAS, Licensee and its sublicensees have developed and/or are developing or evaluating vaccines for the prevention of certain diseases in humans; and

  
 WHEREAS, Licensee desires to obtain a non-exclusive license
under the Technology (as hereinafter defined) in the Field (as hereinafter defined), and Coley desires to grant Licensee such rights and licenses; 
  
 NOW, THEREFORE, in consideration of the premises and covenants contained herein and other good and valuable consideration, the receipt and adequacy of
which are hereby acknowledged, and intending to be legally bound, the Parties hereby agree as follows: 
  

	1.	DEFINITIONS 

  
 1.1 General. Unless otherwise specified, references in this Agreement to any section are references to such section of this Agreement and, unless
otherwise specified, references in any section or definition to any clause are references to such clause of such section or definition. Terms for which meanings are defined in this Agreement shall apply equally to the singular and plural forms of
the terms defined. Whenever the context may permit or require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The term “including” means including, without limiting the generality of any description
preceding such term. Each reference herein to any Person shall include a reference to such Person’s successors and permitted assigns. Unless otherwise specified, references to any agreement, instrument or other document in this Agreement refer
to such agreement, instrument or other document as originally executed or, if subsequently varied, replaced or supplemented from time to time, as so varied, replaced or supplemented and in effect at the relevant time of reference thereto. References
to “dollars” or “$” are to United States dollars. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

 1.2 Defined Terms. As used in this agreement, the following terms shall have the following
respective meanings: 
  
 (a)
“Affiliate” shall mean any individual or entity directly or indirectly controlling or controlled by or under common control with a Party to this Agreement. For purposes of this definition, the term “control” means (i)
direct or indirect ownership of more than fifty percent (50%) of the voting interest in the entity in question, or more than fifty percent (50%) interest in the income of the entity in question; provided, however, that if local law
requires a minimum percentage of local ownership, control will be established by direct or indirect beneficial ownership of one hundred percent (100%) of the maximum ownership percentage that may, under such local law, be owned by foreign interests;
or (ii) possession, directly or indirectly, of the power to direct or cause the direction of management or policies of the entity in question (whether through ownership of securities or other ownership interests, by contract or otherwise).
Notwithstanding the foregoing, “Affiliate” shall not include, in the case of Licensee, Novartis A.G. or any Affiliate of Novartis A.G. (other than Licensee and any of its direct or indirect subsidiaries), so long as Novartis A.G. is
precluded from electing or has not exercised its rights to elect, a majority of the board of directors of Licensee, in accordance with the terms of the Governance Agreement dated as of November 20, 1994, among Ciba-Geigy Limited, Ciba-Geigy
Corporation and Licensee. 
  
 (b)
“Agreement” shall have the meaning set forth in the first paragraph of this Agreement. 
  
 (c) “Antigen” shall mean any and all compounds or compositions or components or formulation of components, other than
Immune Modulator, used to induce, augment, fine-tune or enhance an antigen-specific active response of Licensed Product above the one already induced, augmented or enhanced by Immune Modulator. 
  
 (d) “BLA” shall mean a biologics license
application or similar application filed with the FDA or other appropriate Regulatory Authority to obtain marketing approval for Licensed Product (or a “common technical document” filed in lieu thereof to obtain such approval). 

 
 (e) “Claim” shall mean any claim,
demand, action or other proceedings (including for personal injury, death or disability) by a third party. 
  
 (f) “Coley” shall have the meaning set forth in the first paragraph of this Agreement. 
  
 (g) “Coley Indemnified Party” shall have
the meaning set forth in Section 10.1. 
  
 (h)
“Collaboration Manager” shall have the meaning set forth in Section 4.3. 
  
 (i) “Commercially Reasonable Efforts” shall have the meaning set forth in Section 4.1. 
  
 (j) “Commercialization Plan” shall have the
meaning set forth in Section 4.2(a). 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 2 

 (k) “Confidential Information” shall mean any scientific, technical,
commercial, marketing or other business information furnished, directly or indirectly (including in connection with meetings with Regulatory Authorities or third parties), and whether in writing, orally or otherwise, by one Party (the
“Disclosing Party”) to the other Party (the “Receiving Party”) pursuant to or in connection with this Agreement or the Prior Agreements (including the negotiation of this Agreement and the Prior Agreements) or the
activities or transactions contemplated hereby or thereby. Such Confidential Information may include the identity, nucleotide sequence, or structure of an immunomodulatory oligonucleotide (including the Immune Modulator), the applicability or use of
any immunomodulatory oligonucleotide (including the Immune Modulator) for a particular indication, information relating to the mechanism of immune stimulation for a particular immunomodulatory oligonucleotide (including the Immune Modulator),
information about the composition of, or modifications to the nucleotides or phosphate backbone, as well as any product specifications, trade secrets, know-how (including Know-How), inventions, intellectual property, technical data or
specifications, discovery methods, screening assays or other testing methods, business or financial information, research and development activities, royalty reports, and customer and supplier information. 
  
 (l) “Control” shall mean, with respect to
any intellectual property right, possession of the right (and only to the extent of the right), whether directly or indirectly and whether by ownership, license or otherwise, to assign or grant a license, sublicense or other right to or under such
intellectual property right without violating the terms of any agreement or other arrangement with any third party. 
  
 (m) “Data” shall mean all data and other information included or referenced in a Submission. 
  
 (n) “Development Milestone” shall have the
meaning set forth in Section 3.2. 
  
 (o)
“Development Milestone Payment” shall have the meaning set forth in Section 3.2. 
  
 (p) “Development Plan” shall have the meaning set forth in Section 4.2(a). 
  
 (q) “Disclosing Party” shall have the
meaning set forth in Section 1.2(k). 
  
 (r)
“Donated Licensed Product” shall have the meaning set forth in Section 1.2(mm). 
  
 (s) “Effective Date” shall have the meaning set forth in the first paragraph of this Agreement. 
  
 (t) “EU Associated Countries” shall mean
the territories and countries where Articles 81(1) and 82 of the EU Treaty apply or competition provisions similar thereto apply pursuant to bilateral or multilateral agreements between the European Union and such territories and countries.

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 3 

 (u) “European Economic Area” or “EEA” shall mean an
area comprising the EU Member States, Norway, Liechtenstein and Iceland. 
  
 (v) “FDA” shall mean the United States Food and Drug Administration or any successor entity. 
  
 (w) “Field” shall mean the use of Immune Modulator co-formulated with one or more Antigens as a vaccine that is labeled
solely for use as a prophylactic administered via a Specified Delivery Method to prevent one or more Specified Diseases in humans. The Field specifically excludes labeling any product containing Immune Modulator for the treatment or prevention of
any diseases, indications or disorders other than a Specified Disease in humans, but does not exclude the off-label use of products containing the Immune Modulator by medical professionals or other end users. 
  
 (x) “First Commercial Sale” shall mean,
with respect to a particular Licensed Product and a particular country in the Territory, the first transaction by Licensee or a Sublicensee that transfers to an arm’s-length third party purchaser, for value, title and right of physical
possession of the Licensed Product for use in the Field in the country after such Licensed Product has been granted Regulatory Approval for use in the Field by the competent Regulatory Authorities in such country. Notwithstanding the provisions of
the preceding sentence, transfer of possession and title to an Affiliate or a Sublicensee shall not constitute a First Commercial Sale unless the Affiliate or Sublicensee is an end user of the Licensed Product. With respect to any country of the
EEA, the First Commercial Sale of a Licensed Product in such country shall be deemed to occur on the date of the First Commercial Sale of such Licensed Product in any country of the EEA. 
  
 (y) “Immune Modulator” shall mean Coley’s proprietary immunomodulatory oligonucleotide
whose confidential sequence has been identified by Coley as CpG 7909. 
  
 (z) “Initiation” shall, for the purpose of Phase II Clinical Trials and Phase III Clinical Trials, mean that the following activities have been carried out for the purpose of a given phase: the
clinical lots have been released, the principal investigator has signed the clinical study protocol, the relevant regulatory authorities have approved the clinical trial protocol for such phase, and the Licensed Product has been administered to a
human patient enrolled for purposes of clinical trials in such phase. 
  
 (aa) “IND” shall mean an Investigational New Drug Application in the U.S. or any foreign equivalent document that allows the initiation of human clinical trials in any country in the Territory.

  
 (bb) “Indemnitee” shall have
the meaning set forth in Section 10.3. 
  
 (cc)
“Indemnitor” shall have the meaning set forth in Section 10.3. 
  
 (dd) “Inventions” shall mean all ideas, information, data, writings, development, processes, discoveries, improvements,
methods, modifications, reagents, compositions, formulations, materials, know-how, and other technologies (whether or not 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 4 

 
patentable or copyrightable) that (i) relate to the Immune Modulator and are derived from the use of Technology and (ii) are conceived and reduced to
practice by or on behalf of Licensee during the performance of activities under this Agreement. 
  
 (ee) “Iowa Agreement” shall mean that certain License Agreement by and between CpG ImmunoPharmaceuticals, Inc.
([predecessor to Coley]) and UIRF, dated March 31, 1997, as amended March 7, 2001, as it exists on the Effective Date and is attached hereto as Exhibit A. 
  
 (ff) “Know-How” shall mean all proprietary technical information, know-how, discoveries,
improvements, processes, formulas, data, inventions, sequences, modifications, mechanisms of action, trade secrets, instruction and other intellectual property (other than Patent Rights and the information disclosed or referenced therein) and
reagents, compositions, formulations, and materials (as well as fragments, metabolites, constituents, components, and derivatives thereof), whether or not patentable, that 
  
 (i) are necessary for the development and commercialization of Licensed Products, 
  
 (ii) relate to the Immune Modulator, or, 
  
 (iii) to the extent (but only to the extent) necessary to
permit Licensee to exercise its rights under Section 2.1, relate to manufacturing methods or processes for immunomodulatory compounds (including the Immune Modulator), discovery methods for immunomodulatory compounds (including the Immune
Modulator), and screening assays and other testing methods for immunomodulatory compounds (including the Immune Modulator), and, 
  
 in each case, that exist as of the Effective Date or arise during the Term and are owned, proprietary to, licensed by, Controlled by, or otherwise in the possession of,
Coley or its Affiliates as of the Effective Date or during the Term and are not generally known to others in the field to which such know-how pertains. Except as and to the extent necessary to permit Licensee to exercise its rights under Section
2.1, Know-How shall specifically exclude proprietary technical information, know-how, discoveries, improvements, processes, formulas, data, inventions, sequences, modifications, mechanisms of action, trade secrets, instruction and other intellectual
property and reagents, compositions, formulations, and materials relating to manufacturing methods or processes, discovery methods, and screening assays and other testing methods. 
  
 (gg) “Liability” shall have the meaning set forth in Section 10.1. 
  
 (hh) “Licensed Product” shall mean a
product labeled for use in the Field and consisting of Immune Modulator, up to a maximum dose of 2 mg per administration, co-formulated with one or more Antigens in a single vial, syringe or other suitable container. Licensed Product does not
include any combination with any drug product, vaccine or biological product labeled for any use outside the Field. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 5 

 (ii) “Licensee” shall have the meaning set forth in the first paragraph
of this Agreement. 
  
 (jj) “Licensee
Indemnified Party” shall have the meaning set forth in Section 10.2. 
  
 (kk) “Licensee’s Existing IP” shall mean all intellectual property rights that 
  
 (i) are Controlled by Licensee or its Affiliates prior to the Effective Date; 
  
 (ii) are first Controlled by Licensee or its Affiliates on
or after the Effective Date by, from or through a Person (other than Coley and its Affiliates) that does not have access to the Know-How; or 
  
 (iii) are first Controlled by Licensee or its Affiliates on or after the Effective Date pursuant to a merger, consolidation, acquisition
(whether of all the outstanding stock or all or a portion of the assets of a Person ), or similar transaction with a third party, 
  
 including that intellectual property of Licensee and its Affiliates specified on Exhibit B. 
  
 (ll) “Major Country” shall mean the United States, Canada, France, Germany, Italy, the
United Kingdom, or Japan. 
  
 (mm) “Net
Sales” shall mean the gross amount invoiced by Licensee and/or a Sublicensee on account of sales of Licensed Products to third parties in the Territory, less the total of the following deductions to the extent they are actually incurred and
not billed separately to the customer: 
  
 (i)
trade, cash, and/or quantity discounts not already reflected in the amount invoiced; 
  
 (ii) excise, sales and other consumption taxes and customs duties to the extent included in the invoice price; 
  
 (iii) freight, insurance and other transportation charges to
the extent included in the invoice price; 
  
 (iv) amounts repaid or credited by reason of rejections and defects; 
  
 (v) returns or retroactive price reductions; and 
  
 (vi) payments and rebates directly related to the sale of Licensed Products, 
  
 accrued in accordance with generally accepted accounting principles, paid or deducted pursuant to agreements (including managed care
agreements) or governmental regulations. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 6 

 Net Sales shall not include reasonable quantities of any given Licensed Product distributed by Licensee
and its Sublicensees at no charge to third parties for pre-clinical, clinical, or regulatory purposes or in connection with patient assistance programs or other charitable purposes (“Donated Licensed Products”); provided,
however, that the number of Donated Licensed Products of a particular Licensed Product shall not exceed [****] percent ([*]%) of the total units of the Licensed Product invoiced by Licensee and its Sublicensees for consideration on an
arm’s length basis during the applicable Royalty Quarter. In the event that Donated Licensed Products of a particular Licensed Product exceed [****] percent ([*]%) of the total units of the Licensed Product invoiced by Licensee and its
Sublicensees during the applicable Royalty Quarter, then Licensee shall make Royalty Payments to Coley on those Donated Licensed Products which exceed the [****] percent ([*]%) cap. Net Sales for purposes of calculating the Royalty Payments due to
Coley on the excess Donated Licensed Products shall be calculated by taking the average Net Sales price of the relevant Licensed Product invoiced during the applicable Royalty Quarter. 
  
 In the case of any sale or other disposal of a Licensed Product between or among either Licensee/Sublicensee and their
respective Affiliates for resale or Licensee and Sublicensee for resale, Net Sales shall be calculated as above by taking the average Net Sales price of the Licensed Product invoiced by the receiving Person during the applicable Royalty Quarter.
Sales between or among Licensee, Sublicensee and their respective Affiliates shall be excluded from the computation of Net Sales except where such Sublicensees or Affiliates are end users. In the case of any other sale or other disposal for value,
such as barter or counter-trade, of any Licensed Product, or part thereof, other than in an arm’s length transaction exclusively for money, Net Sales shall be calculated as above on the fair market value of the consideration given. 

 
 (nn) “Option Period” shall have the
meaning set forth in Section 5.2(b). 
  
 (oo)
“Option Right” shall have the meaning set forth in Section 5.2(b). 
  
 (pp) “Party” shall have the meaning set forth in the first paragraph of this Agreement. 
  
 (qq) “Patent Rights” shall mean 

 
 (i) all patents and patent applications, including
provisional patent applications, that relate to the Immune Modulator, 
  
 (ii) all national, regional and international patent applications filed either from such patent applications or provisional applications or from an application claiming priority from either of these, including
divisionals, continuations, continuations-in-part, provisionals, converted provisionals and continued prosecution applications, in each case that relate to the Immune Modulator, 
  
 (iii) any and all patents that have issued or in the future issue from the foregoing patent applications,
including utility models, petty patents and design patents and certificates of invention, that relate to the Immune Modulator, 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 7 

 (iv) any and all extensions or restorations by existing or future extension or
restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications described in clauses (i), (ii) and (iii),
and, 
  
 (v) to the extent (but only to the
extent) necessary to permit Licensee to exercise its rights under Section 2.1, patents or patent applications relating to manufacturing methods or processes for immunomodulatory compounds (including the Immune Modulator), discovery methods for
immunomodulatory compounds (including the Immune Modulator), and screening assays and other testing methods for immunomodulatory compounds (including the Immune Modulator), 
  
 in each case, owned, Controlled or licensed (other than by Licensee or its Affiliates or Sublicensees pursuant to Sections 2.4 or
5.1(c)(ii)(1) and (3)) by Coley or its Affiliates as of the Effective Date or during the Term and that exist as of the Effective Date or arise during the Term and under which Coley or its Affiliates have the right, whether directly or indirectly and
whether by ownership, license or otherwise (other than from Licensee or its Affiliates or Sublicensees pursuant to Sections 2.4 or 5.1(c)(ii)(1) and (3)), to disclose, assign, or grant licenses, sublicenses or any other right, including the Patent
Rights listed on Exhibit C, as amended from time to time in accordance with this Agreement. Except as and to the extent necessary to permit Licensee to exercise its rights under Section 2.1, the Patent Rights shall specifically exclude
patents or patent applications relating to manufacturing methods or processes, discovery methods, and screening assays and other testing methods. 
  
 (rr) “Person” shall mean an individual, sole proprietorship, partnership, limited partnership, limited liability
partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture, or similar entity or organization, including a government or political subdivision, department or agency of a
government, or an academic or research institution. 
  
 (ss) “Phase I Clinical Trials” shall mean clinical studies in subjects to evaluate the safety and tolerance, pharmacokinetic and pharmacodynamic properties, dosing interval, and/or absorption, distribution, metabolism, and
excretion (ADME) of the candidate vaccine. 
  
 (tt) “Phase II Clinical Trials” shall mean dose-ranging trials to evaluate efficacy and/or immunogenicity and safety in the targeted patient population and/or to define the optimal dosing regimen. 
  
 (uu)“Phase III Clinical Trials” shall mean
short-term and/or long-term controlled trials to confirm the efficacy and/or immunogenicity and safety of the drug in larger, targeted patient populations. 
  
 (vv)“Pre-Commercial Manufacture Agreement” shall have the meaning set forth in Section 5.2(a). 
  
 (ww) “Prior Agreements” shall mean that
certain Material Transfer and Evaluation Agreement, effective February 11, 2002, between the Parties, as amended by 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 8 

 
Amendment #1 thereto, that certain Confidentiality Agreement, dated October 1, 2001, between the Parties, and that certain Mutual Confidentiality Agreement,
dated March 22, 2000, between the Parties, as amended June 26, 2001. 
  
 (xx) “Receiving Party” shall have the meaning set forth in Section 1.2(k). 
  
 (yy) “Regulatory Approval” shall mean the marketing authorization (independent of pricing approval or reimbursement
approval) of a Licensed Product in a country in the Territory, in each case by the appropriate Regulatory Authority. 
  
 (zz) “Regulatory Authority” shall mean, with respect to each country in the Territory, the government agency or health
authority that regulates and is responsible for granting approvals for the manufacture, marketing and/or sale of pharmaceutical products in such country. 
  
 (aaa) “Royalty Payments” has the meaning set forth in Section 3.4(a). 
  
 (bbb) “Royalty Period” shall mean the
partial Royalty Quarter commencing on the date of the First Commercial Sale in any country in the Territory and every complete or partial Royalty Quarter thereafter with respect to which Licensee has the obligation to make Royalty Payments under
Section 3. 
  
 (ccc) “Royalty
Report” shall have the meaning set forth in Section 3.4(b). 
  
 (ddd) “Royalty Quarter” shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. 
  
 (eee) “Royalty Year” shall mean each
successive period of twelve (12) months commencing on January 1 and ending on December 31. 
  
 (fff) “Specifications” shall mean the drug substance and/or product quality specifications, release test methods, and
typical batch release data relating to the Immune Modulator or, solely in the case of the use of the term in Section 5.2(c)(iii), other immunomodulatory oligonucleotides. 
  
 (ggg) “Specified Delivery Method” shall mean administration of a product by an
intramuscular or subcutaneous injection. 
  
 (hhh) “Specified Disease” shall mean Hepatitis C [*************************]. At any time and from time to time, and with respect to any one or more Specified Diseases, Licensee may provide notice that it wishes to delete
one or more Specified Diseases from this definition. Any such notice shall be accompanied by Licensee’s written certification that 
  
 (i) Licensee has in good faith determined that there is no reasonable basis, for either scientific or commercial reasons, for Licensee to
commercialize a Licensed Product for a particular Specified Disease or 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 9 

 (ii) Licensee is no longer working with respect to a particular Specified Disease in the
Field. 
  
 Effective sixty (60) days following any notice delivered by Licensee
pursuant to the preceding sentence, this definition shall, without further action on the part of either Party, be for all purposes deemed to be amended by deleting therefrom the Specified Disease(s) specified in Licensee’s notice. 

 
 (iii) “Sublicensee” shall mean any
Person who receives a sublicense of the license rights granted to Licensee pursuant to and in accordance with this Agreement. 
  
 (jjj) “Submission” shall mean the acceptance for filing by the relevant Regulatory Authority of an application to obtain
Regulatory Approval. 
  
 (kkk)
“Technology” shall mean the Patent Rights and Know-How. 
  
 (lll) “Term” shall have the meaning set forth in Section 6.1. 
  
 (mmm) “Territory” shall mean all the countries of the world. 
  
 (nnn) “UIRF” means the University of Iowa
Research Foundation. 
  
 (ooo) “Valid
Claim” shall mean any claim of a pending patent application which has not been abandoned or finally rejected without the right of appeal, or any claim from an issued and unexpired patent included within the Patent Rights which has not been
revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, and which has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer or
otherwise. Notwithstanding the foregoing, if a claim of a pending patent application in a specific country has not issued as a claim of an issued patent within ten (10) years after the first filing date of the first application in the country from
which such pending claim claims priority, such pending claim shall cease to be a Valid Claim for purposes of this Agreement unless and until such claim becomes an issued claim of an issued patent. 
  
 (ppp) “Valid Patent Claim” shall mean any
claim from an issued and unexpired patent included within the Patent Rights which has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, and which has not been
disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise. 
  
 (qqq) “Withholding Taxes” shall have the meaning set forth in Section 3.5(a). 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 10 

	2.	LICENSE GRANTS. 

  
 2.1 License Grant to Licensee. Subject to the terms of this Agreement, Coley hereby grants to Licensee, and Licensee hereby accepts, during the
Term, a non-exclusive, royalty-bearing license, with the right to grant sublicenses solely as provided in Section 2.3, under the Technology, and to use the Immune Modulator in connection therewith, in each case to make, have made, use, have used,
sell, have sold, offer for sale, and import Licensed Products in the Field in the Territory. 
  
 2.2 Limitations. Except as specifically allowed in Section 2.1 above, Licensee shall have no rights under this Agreement to use the Immune Modulator for any purpose. No other rights, express or implied, are
granted to Licensee except as expressly granted pursuant to this Agreement. 
  
 2.3 Sublicenses. Licensee shall not sublicense any rights it obtains herein to any Person other than an Affiliate of Licensee unless Licensee has first obtained the written consent of Coley to such sublicense,
such consent not to be unreasonably withheld. The sublicensing rights granted to Licensee hereunder shall be limited to Licensed Products developed or sold by the Licensee. Licensee shall not grant Sublicensees rights to develop or sell Licensed
Products that are not/have not been developed or sold by Licensee. Each sublicense agreement with a Sublicensee shall be subject and subordinate to this Agreement and shall contain provisions substantially similar to the provisions of this
Agreement. Sublicensees that are Affiliates of Licensee may further sublicense any rights they obtain herein to other Affiliates of Licensee. No Sublicensee may further sublicense any rights it obtains hereunder to any Person that is not an
Affiliate of Licensee without first obtaining the written consent of Coley to such further sublicense. In the event of early termination of this Agreement, any sublicense agreement with any Sublicensee shall provide for the termination of the
sublicense, or the conversion to a license directly between such Sublicensee and Coley on substantially the same terms as the sublicense agreement, at the option of the Sublicensee; provided, however, that such Sublicensee is in good
standing under the sublicense agreement; and provided, further, that, in no event shall Coley have greater obligations to such Sublicensee than it has to Licensee hereunder. 
  
 2.4 License Grant to Coley. Licensee shall grant, and hereby grants, to Coley and its Affiliates a non-exclusive,
royalty-free, perpetual, fully paid-up license, with the right to grant sublicenses, to practice the Inventions and any intellectual property rights therein to the extent necessary (but only to the extent necessary) for Coley to practice the
Technology outside the Field; that is, if in the absence of such a license from Licensee, Coley would be unable to practice the Technology outside the Field. 
  
 2.5 Provision of Know-How and Cooperation. Coley shall provide Licensee and its Sublicensees with access to all Know-How and all other information
owned or Controlled by or otherwise in the possession of Coley or its Affiliates that is necessary or useful for purposes of the development, regulatory approval, and commercialization of Licensed Products in the Territory and all other activities
of Licensee contemplated by this Section 2. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 11 

	3.	PAYMENTS AND ROYALTIES. 

  
 3.1 Up-Front Payment. In partial consideration of Coley’s investment in the Technology and the non-exclusive license granted to Licensee
pursuant to Section 2.1, Licensee shall make a non-refundable, up-front license fee payment of [***********] dollars ($[*********], Such up-front license fee shall be payable by Licensee within twenty (20) days following its receipt of Coley’s
invoice therefor. 
  
 3.2 Development Milestone Payments.
Licensee shall pay Coley the amount corresponding to each development milestone achieved by Licensee or its Affiliates or Sublicensees hereunder (the “Development Milestones”) set forth below (each, a “Development Milestone
Payment”) . Each Development Milestone Payment shall be payable by Licensee within twenty (20) days following its receipt of Coley’s invoice therefor. If any Development Milestone is reached without achieving a preceding Development
Milestone, then the amount which would have been payable on achievement of the preceding Development Milestone shall be payable upon achievement of the following Development Milestone. For example, if a Phase III Clinical Trial is initiated for a
Licensed Product without initiating a Phase II Clinical Trial, then a total of $[*******] will be due upon the initiation of the Phase III Clinical Trial. Except as otherwise expressly provided herein, each Development Milestone Payment shall be
payable only once for a Licensed Product regardless of the number of INDs filed, Phase II Clinical Trials or Phase III Clinical Trials conducted, Submissions made, or Regulatory Approvals obtained in a given country, the number of countries in which
Development Milestones are achieved, or the number of improvements or follow-on Licensed Products that are derived from such Licensed Products. In the event that Licensee or its Affiliates or Sublicensees discontinues the development or
commercialization of a Licensed Product for the prevention of a Specified Disease in favor of another Licensed Product for the prevention of the same Specified Disease, then any Development Milestone Payments made with respect to the first Licensed
Product shall be credited against any Development Milestone Payments otherwise payable with respect to the subsequent Licensed Product. In the event that Licensee develops a Licensed Product that contains Antigens for two or more of the three
Specified Diseases in the Field in a single vaccine, Development Milestones will be paid for each such Specified Disease. 
  

							
	 Development Milestone Payments

	  	For the First Licensed
Product for Each
Specified Disease (i.e.,
********************)

	  	Each Additional Licensed
Product for a Specified
Disease after the First
Licensed Product for the
Specified Disease

	 Filing of an IND or equivalent
	  	$	[*******]	  	 	 
	 Initiation of Phase II Clinical Trial
	  	$	[*******]	  	 	 
	 Initiation of Phase III Clinical Trial
	  	$	[*******]	  	 	 
	 Regulatory Submission-US
	  	$	[*******]	  	$	[*********]
	 Submission in the first next Major Country
	  	$	[*******]	  	$	[*******]
	 Regulatory Approval - US
	  	$	[*********]	  	$	[*********]
	 Regulatory Approval in the first next Major Country
	  	$	[*********]	  	$	[*********]

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 12 

 3.3 Minimum Annual Payments. Licensee shall make the following minimum annual payments to Coley:

  
 (a) on the first anniversary of the Effective
Date, [**************] dollars ($[******]); 
  
 (b) on the second anniversary of the Effective Date, [*******************] dollars ($[*******]); and 
  
 (c) on the third anniversary of the Effective Date and each succeeding anniversary of the Effective Date that occurs prior to the
termination of the Royalty Period, [*************************] dollars ($[*******]). 
  
 Each such payment shall be payable by Licensee within twenty (20) days of its receipt of Coley’s invoice therefor and shall be fully creditable against any Development Milestone Payments or Royalty Payments falling due to Coley during
the two years following the date on which the payment is made. 
  
 3.4 Royalty Payments. 
  
 (a)
Royalty Payments Due. Licensee shall pay to Coley royalty payments on annual Net Sales of each Licensed Product by Licensee and Sublicensees in the amounts set forth below (“Royalty Payments”): 
  
 (i) With respect to Net Sales of the Licensed Product made
in a particular country during the period in which the Licensed Product is covered by a Valid Patent Claim in such country, the Licensee shall pay Coley a royalty of [*********************] percent ([***]%) of such Net Sales. 
  
 (ii) With respect to Net Sales of the Licensed Product made
in a particular country during the period in which the Licensed Product is covered by a Valid Claim but is not covered by a Valid Patent Claim in such country, the Licensee shall pay Coley 
  
 (1) a royalty of {****************] percent ([***]%) of
such Net Sales made prior to the fifth anniversary of the Effective Date and 
  
 (2) (A) a royalty of [*******************] percent ([***]%) of such Net Sales made on or after the fifth anniversary of the Effective Date plus, (B) in the event (but only in the event) the Licensed Product should
come to be covered by a Valid Patent Claim in the country on or after the fifth anniversary of the Effective Date but prior to the tenth anniversary of the Effective Date, an additional royalty equal to the difference between (x) the royalty that
would have been payable under Section 3.4(a)(i) with respect to Net Sales of the Licensed Product in the country if such Licensed Product had been covered by a Valid Patent Claim in the country beginning on the fifth anniversary of the Effective
Date and continuing until the date the Licensed Product came actually to be covered by a Valid Patent Claim in the country and (y) the royalty actually paid with respect to Net Sales of the Licensed Product in the country during the period beginning
on the fifth anniversary of the Effective Date and continuing 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 13 

 
until the date the Licensed Product came actually to be covered by a Valid Patent Claim in the country. 
  
 Amounts payable pursuant to clause (2)(B) of this Section 3.4(a)(ii) shall be paid by
Licensee to Coley within sixty (60) days following the end of the Royalty Quarter during which Coley gives notice to Licensee that the Licensed Product has come to be covered by a Valid Patent Claim in the country. 
  
 (iii) With respect to Net Sales of the Licensed Product made
in a particular country during the period in which the Licensed Product is not covered by a Valid Claim in such country, the Licensee shall pay Coley a royalty of [*******************] percent ([***]%) of such Net Sales. 
  
 The Royalty Payment due with respect to the sale of a specific Licensed Product under this
Section 3.4(a) shall be determined on the basis of the country in which the Licensed Product is sold, not the country in which the Licensed Product is manufactured. In any event, only one (1) Royalty Payment shall be due under this Section 3.4(a)
per Licensed Product sold. Except as and to the extent contemplated by Section 3.7, Royalty Payments shall not be subject to any offsets or credits for royalties or payments made to third parties by Licensee for third parties’ technologies
which are utilized or incorporated into the Licensed Product. 
  
 (b) Tender of Royalty Payments and Royalty Reports. Within thirty (30) days after the conclusion of each Royalty Quarter, Licensee shall, except as otherwise contemplated by Section 3.4(a)(ii), tender payment
of any Royalty Payments due under this Agreement and shall concurrently deliver to Coley a report on the Net Sales activity of Licensee and Sublicensees during such Royalty Quarter (the “Royalty Report”). If no Royalty Payment is due, the
Royalty Report shall so state. All such Royalty Reports shall be considered Confidential Information of both Parties under this Agreement. Royalty Reports shall contain at least the following information: 
  
 (i) Net Sales of any Licensed Products sold by Licensee and
Sublicensees on a country-by-country and Licensed Product-by-Licensed Product basis (including number of units sold), during the applicable Royalty Quarter; 
  
 (ii) total Royalty Payments due with respect to Net Sales of each Licensed Product in each country; and 
  
 (iii) the total number of Donated Licensed Products on a
Licensed Product-by-Licensed Product basis during the applicable Royalty Quarter, and the nature of the recipients of all such Donated Licensed Products. 
  
 (c) Period During Which Royalties Are Payable. Licensee’s Royalty Payment obligations under this Section 3.4 shall become
effective on a country-by-country and Licensed Product-by-Licensed Product basis upon the First Commercial Sale of a particular Licensed Product in a particular country in the Territory and continuing thereafter with respect to such country and such
Licensed Product until the later to occur of (i) the expiration or termination of the last Valid Claim of a Patent Right covering such Licensed Product in such country or (ii) ten 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 14 

 
(10) years from the First Commercial Sale of the Licensed Product in such country. Upon expiration of the period during which Licensee is obligated to make
Royalty Payments with respect to a specific Licensed Product in specific country in the Territory, the rights granted to Licensee pursuant to Section 2.1 with respect to such Licensed Product in such country shall become perpetual, irrevocable,
fully paid-up and royalty-free. 
  
 3.5 Withholding;
Payments. 
  
 (a) Any payments made by
Licensee to Coley under this Agreement shall be reduced by the amount that Licensee is required to withhold pursuant to any applicable tax law (“Withholding Taxes”). Licensee shall submit reasonable proof of payment of the Withholding
Taxes to Coley within a reasonable period of time after such Withholding Taxes are remitted to the proper taxing authority. 
  
 (b) Any payments due under Section 3 shall be made in dollars, using a mutually acceptable method of payment. With respect to sales of a
Licensed Product invoiced in a currency other than dollars, the Net Sales and amounts due to Coley hereunder shall be expressed in the domestic currency of the Party making the sale, together with the dollar equivalent of the amount payable to
Coley, calculated using the interbank exchange rate in force on the last working day of the Royalty Quarter in which the Net Sales were made as published by the Wall Street Journal (U.S. Eastern edition). 
  
 3.6 Late Payments. Any payments due under this Section 3 that are not
made on or before the date specified under the terms of this Agreement shall bear interest, to the extent permitted by law, at a rate equal at all times to the prime rate of interest announced publicly from time to time by Citibank, N.A., plus [***]
percent ([*]%), but in no case higher than the maximum rate permitted by applicable law. 
  
 3.7 Third Party Licenses. In the event that Licensee must obtain one or more royalty-bearing licenses from one or more third parties during the Royalty Period in order for Licensee and/or Sublicensees to
practice the rights granted hereunder to the Patent Rights without infringing such third party’s rights, Licensee may offset [*****] percent ([**]%) of any such third party payments against the Royalty Payments otherwise payable to Coley
hereunder in the same or any subsequent Royalty Quarter; provided, however, that in no event shall aggregate Royalty Payments with respect to any Licensed Product be reduced by more than [*****] percent ([**]%) for any Royalty Quarter.
Offsets for any such third party royalty payments for Net Sales of a particular Licensed Product may be applied only against Royalty Payments due hereunder for the Net Sales of such Licensed Product. 
  
 3.8 Audit of Records. 
  
 (a) Licensee, its Affiliates and Sublicensees shall keep and
maintain records of sales, importations, and other dispositions of Licensed Products. The records required by this Section shall be maintained and available for inspection for a period of five (5) years following the Royalty Year to which they
pertain. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 15 

 (b) Coley shall have the right, at Coley’s expense, to examine, through an
independent certified public accounting firm reasonably acceptable to Licensee, those records of Licensee and Sublicensees as may be reasonably necessary to confirm the accuracy of the Royalty Reports. Any such examination shall be made only upon
not less than ten (10) day’s prior written notice to Licensee or Sublicensee, as the case may be, during regular business hours, and within three (3) years after the end of Royalty Period; provided, however, that such examination
shall not take place more often than once per Royalty Year and shall not cover such records for more than the preceding three (3) Royalty Years. Such accounting firm shall report to Coley only the final audited Royalty Payment amounts to be paid by
Licensee. 
  
 (c) In the event that any such
inspection shows an underreporting or an underpayment in excess of [****] percent ([*]%) for any consecutive twelve (12) month period, then Licensee shall pay the reasonable costs of such examination and in any event shall pay any additional sum,
including interest charges (at a rate equal at all times to the prime rate of interest announced publicly from time to time by Citibank, N.A., plus [***] percent ([*]%), but in no case higher than the maximum rate permitted by applicable law) on any
such additional sum shown to be due to Coley. 
  

	4.	DEVELOPMENT; DILIGENCE OBLIGATIONS; ADVISORY COMMITTEE. 

  
 4.1 Diligence Generally. Licensee shall use commercially reasonable efforts consistent with the efforts and resources normally used in good faith
and fair dealing for a product of its own discovery of similar market potential at a similar stage in its product life, taking into account the competitiveness of the market place, the proprietary position of the product, the regulatory structure
involved, the profitability of the applicable products and other relevant factors (“Commercially Reasonable Efforts”), (a) to pursue the development, commercialization, and marketing of at least one Licensed Products for each Specified
Disease in the Field in each Major Country and (b) to undertake investigations and actions required to obtain appropriate Regulatory Approval therefor. 
  
 4.2 Development and Commercialization Plans. 
  
 (a) Consistent with Section 4.1: 
  
 (i) Licensee shall prepare and provide Coley with a development plan (“Development Plan”) for each Specified Disease within the
Field. Each Development Plan shall set forth anticipated activities, plans and timelines for the development of Licensed Products targeting the relevant Specified Disease (including regulatory timelines for each Major Country). Following initial
submission, each Development Plan shall be updated by Licensee at least annually for each Specified Disease in the Field. Annual updates shall include a description of all significant activities and results since the date of the most recent
Development Plan. An initial Development Plans for each Specified Disease included in the Field shall be delivered not later than one hundred eighty (180) days prior to the date upon which Licensee in good faith anticipates Phase I Clinical Trials
will begin for the Specified Disease. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 16 

 (ii) Licensee shall provide Coley with a commercialization plan (“Commercialization
Plan”) for each Licensed Product no later than one (1) year prior to the anticipated First Commercial Sale of the Licensed Product in a Major Country. Each Commercialization Plan shall set forth projected annual Net Sales and anticipated
activities, plans and timelines for the commercialization of the relevant Licensed Product. 
  
 Each Development Plan and Commercialization Plan shall be prepared by Licensee in good faith and shall reflect Licensee’s intentions and projection as of the date of its delivery to Coley. 
  
 4.3 Collaboration Manager. Each Party shall appoint one individual who
shall serve as such Party’s primary contact with respect to this Agreement and any issues that may arise hereunder (a “Collaboration Manager”). Each Party shall at all times keep the other Party informed of the identity of the
Collaboration Manager. 
  
 4.4 Regulatory Approvals.

  
 (a) Licensee shall use Commercially
Reasonable Efforts to submit registration dossiers to the relevant Regulatory Authorities with respect to all necessary Regulatory Approvals in each Major Country. 
  
 (b) Licensee shall have the right to obtain Regulatory Approvals, which shall be held by and in the name of
Licensee, and Licensee shall own all Submissions and Data in connection therewith. All pricing, formulary and marketing approvals shall also be obtained by and in the name of Licensee, and Licensee will be the principal interface and will otherwise
handle all interactions with Regulatory Authorities concerning any Licensed Products including, to the extent legally possible, being the sole contact with such Regulatory Authorities, subject to the rights of Coley under this Section 4.4.

  
 (c) Each Party shall have full access to and
the right to reference any NDAs and/or their foreign equivalent based on Immune Modulator owned by the other Party, its Affiliates, and/or sublicensees or any third party filing such NDAs and/or their foreign equivalent on behalf of such Party, its
Affiliates, or its sublicensees; provided, however, that such rights are subject to the prior written consent of the Person owning the NDA or foreign equivalent as the case may be and any information contained therein. In the event
that a Party or its Affiliates is the owner of such NDA or foreign equivalent as the case may be or information contained therein, such Party shall not, and shall cause its Affiliates not to, unreasonably withhold or delay consent. In the event that
a third party is the owner of such NDA or foreign equivalent or information contained therein, the Parties agree to reasonably cooperate to obtain such necessary third party consents. Notwithstanding the foregoing, the rights granted to a Party to
access and reference any NDAs and/or their foreign equivalent, as contemplated herein, shall not extend to such Party’s sublicensees without the prior written consent of the Person owning the NDA or foreign equivalent, such consent to be at the
sole discretion of such owning Person. 
  
 (d) To
the extent not prohibited by law or regulation, Coley shall have right to have one (1) representative (i) attend (but not participate in) any material meetings between Licensee and any Regulatory Authority with respect to Licensed Products and (ii)
listen to (but 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 17 

 
not participate in) any material telephone conversation between Licensee and any Regulatory Authority with respect to Licensed Products that is pre-scheduled
between Licensee and the relevant Regulatory Authority. Licensee will use reasonable efforts (i) to provide Coley with as much advance notice of any such meeting or telephone call as is reasonably possible in the circumstances and, (ii) to the
extent reasonably possible, to provide Coley, at least five (5) business days before any such meeting, with copies of all documents, correspondence and other materials which are relevant to the matters to be addressed at any such meeting or in any
such telephone call (it being understood that in no event will the provisions of clause (i) or (ii) of this sentence require Licensee to delay any meeting or telephone call with a Regulatory Authority). Licensee will also provide Coley with access
to all exchanges of material correspondence related to activities conducted pursuant to this Agreement with any Regulatory Authority. Notwithstanding the foregoing, Licensee will have sole discretion as to the regulatory strategy and decision-making
for any Licensed Product. 
  
 (e) Licensee shall
have the sole right to obtain all pricing and reimbursement approvals in all countries in the Territory in which Licensed Products shall be sold. 
  
 4.5 Cooperation by Coley. Coley shall, upon request by Licensee, cooperate with Licensee in all reasonable respects with regard to Licensee’s
activities relating to the obtaining of all necessary Regulatory Approvals for Licensed Products. 
  

	5.	TRANSFER AND SUPPLY OF MATERIALS; MARKING. 

  
 5.1 Transfer of Materials.  
  
 (a) Immune Modulator is Proprietary. Licensee acknowledges and agrees, and shall cause its Sublicensees to acknowledge and agree,
that, subject always to Licensee’s Existing IP and without in any way compromising, limiting, qualifying or otherwise restricting the rights of Licensee and its Affiliates therein and thereto or with respect to any Invention, as between the
Parties, (i) the Immune Modulator is proprietary to and owned by Coley, (ii) it has no ownership rights in the Immune Modulator, and (iii) the Immune Modulator may be the subject of one or more claims in the Patent Rights. 
  
 (b) Use and Transfer. Licensee acknowledges and
agrees, and shall cause its Sublicensees to acknowledge and agree, that it shall not at any time prior to the earlier of the expiration of the Term and such time as the Immune Modulator is not covered by a Valid Claim in a particular country:

  
 (i) use Immune Modulator for any purpose
other than the purposes as set forth in this Agreement in such country; 
  
 (ii) except as otherwise contemplated by this Agreement, distribute, transfer, or provide access to Immune Modulator to any third party in such country; 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 18 

 (iii) subject to Licensee’s Existing IP, alter or in any way modify any DNA sequence
in Immune Modulator in such country; provided, however, that this clause (iii) shall not in any way limit the right of Licensee, its Affiliates and Licensee’s and its Affiliates’ sublicensees to use or exploit Licensee’s
Existing IP or in any way compromise, limit, qualify or otherwise restrict the rights of Licensee and its Affiliates in and to Licensee’s Existing IP; or 
  

(iv) seek to obtain intellectual property protection for the Immune Modulator in such country. 
  
 (c) Remedies. In the event Licensee and its
Affiliates (or any Sublicensee as the case may be) at any time fail to comply with the restrictions set forth in Section 5.1(b), in addition to any other remedies Coley may have at law or in equity, (i) in those countries other than the countries of
the EEA and the EC Associated Countries, Licensee agrees to assign, and hereby assigns, to Coley (and shall require its Sublicensees to assign to Coley), all right, title, and interest in and to any and all information, data, results, discoveries,
assays, and inventions arising from such prohibited use; and (ii) in the countries of the EEA and the EC Associated Countries, Licensee shall grant, and hereby grants, to Coley (and shall require its Sublicensees to grant to Coley) (1) a
non-exclusive, royalty-free, fully paid-up, perpetual right and license (with the right to sublicense) in and to any and all information, data, results, discoveries, assays, and inventions arising from such prohibited use to the extent that the
foregoing are either not improvements to the Technology or are severable improvements to the Technology, (2) an exclusive, royalty-free, fully paid-up right and license (with the right to sublicense) in and to any and all information, data, results,
discoveries, assays, and inventions arising from such prohibited use to the extent that the foregoing are non-severable improvements to the Technology, and/or (3) a non-exclusive (with Licensee or Sublicensee as the case may be) royalty-free, fully
paid-up right and license (with the right to sublicense) to any and all information, data, results, discoveries, assays, and inventions arising from such prohibited use to the extent that the foregoing are severable improvements to the Technology
which cannot be licensed to third parties without disclosing Know-How to such third parties. 
  
 5.2 Manufacture of Immune Modulator; Regulatory Filings and Manufacturing Information  
  
 (a) Supply of Immune Modulator Prior to Commercial Sale. 
  
 (i) Coley shall provide Licensee and its Affiliates and Sublicensees with reasonable research, development
and clinical quantities of the Immune Modulator to permit Licensee and its Affiliates and Sublicensees to conduct the research, development and clinical activities contemplated hereby. Coley shall provide such Immune Modulator to Licensee and its
Affiliates or Sublicensees at Coley’s fully loaded cost, defined as the direct expense associated with the production, shipment, validation and release of such quantities of Immune Modulator supplied, plus [***********] percent ([**]%). Coley,
at its sole cost and expense, shall be responsible for any scale up activities required to comply with its obligations under the preceding sentence. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 19 

 (ii) Coley shall deliver Immune Modulator to Licensee, its Affiliate or its Sublicensee,
as the case may be, pursuant to this Section 5.2(a) within twenty (20) days of receipt of the requesting Person’s purchase order therefor. Such delivery shall be made D.D.U. (as defined in Incoterms 2000) the requesting Person’s facility
in North America or Europe, as specified in the requesting Person’s purchase order. Title and risk of loss with respect to Immune Modulator supplied by Coley pursuant to this Section 5.2(a) shall pass to the requesting Person upon delivery of
the Immune Modulator at the requesting Person’s facility in North America or Europe, as specified in the requesting Person’s purchase order. 
  
 (iii) Coley warrants that, at the time of delivery of Immune Modulator to the requesting Person pursuant to this Section 5.2(a), such
Immune Modulator (1) will have been manufactured, stored and shipped in accordance with applicable good manufacturing practices and all other applicable laws, rules or regulations; (2) have been manufactured in accordance with the Immune Modulator
Specifications; and (3) not be adulterated or misbranded under the U.S. Food, Drug and Cosmetic Act, as amended, or other applicable laws, rules or regulations. The requesting Person shall have the right to reject non-conforming Immune Modulator.

  
 (iv) Coley shall maintain, or cause to be
maintained, all records relating to the production, shipment, validation and release of Immune Modulator supplied to requesting Persons pursuant to this Section 5.2(a) that are necessary to comply with all applicable laws, rules and regulations. All
such records shall be maintained for such period as may be required by applicable law, rule or regulation and shall be available for audit by Licensee and its Affiliates or Sublicensees during regular business hours upon reasonable prior notice by
any such Person to Coley. 
  
 (b) Optional
Right to Supply Immune Modulator for Licensed Products for Commercial Sale. 
  
 (i) Without limiting Licensee’s rights otherwise granted under this Agreement, Licensee hereby grants, and will require its
Sublicensees to grant, Coley an exclusive right and option under Coley’s retained rights to manufacture and supply (or have a third party manufacture and supply on Coley’s behalf) Immune Modulator to be used in Licensed Products for
commercial sale (the “Option Right”). Coley may exercise its Option Right at any time during the period commencing on the Effective Date and ending eighteen (18) months thereafter (the “Option Period”). If Coley does not elect to
exercise the Option Right or fails to exercise the Option Right within the Option Period, then Coley shall have no right to manufacture or have a third party manufacture and supply Immune Modulator to Licensee or Sublicensee for use hereunder. If
Coley exercises its Option Right within the Option Period, Licensee and Coley will negotiate in good faith a supply agreement for Coley to supply Immune Modulator to Licensee at Coley’s fully loaded cost, defined as the direct expense
associated with the production, shipment, validation and release of Immune Modulator supplied, plus [***********] percent ([**]%). If Coley and Licensee or Sublicensee, as the case may be, are unable, despite good faith negotiations, to negotiate a
supply agreement within three (3) months of Coley’s exercise of the Option Right, then Coley shall have no right to manufacture or have a third party manufacture and supply Immune Modulator to Licensee or Sublicensee, as the case 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 20 

 
may be, for use as contemplated hereunder; provided, however, that Licensee, or Sublicensee as the case may be, shall not offer any third party
such a right on terms and conditions more favorable then those last offered to Coley without first offering such terms and conditions to Coley. 
  
 (ii) It shall be a condition to Coley’s ability to exercise the Option Right that Coley have supplied to Licensee or Sublicensee, as
the case may be, a validation package, reasonably satisfactory to Licensee or Sublicensee, as the case may be, for the manufacturing process at the final proposed manufacturing scale in the final proposed manufacturing location. The validation
package shall conform with current industry practice and detail the validation of the manufacturing process and all associated analytical methods as well as all equipment and facilities to be used during the manufacture and shall provide sufficient
information to permit Licensee or Sublicensee, as the case may be, to effectively evaluate whether the proposed manufacturing facility and associated manufacturing systems and documentation will comply with good manufacturing practices within the
pharmaceutical industry and all EEA and U.S. regulatory requirements. 
  
 (c) Manufacturing Information. In the event that Coley does not exercise its Option Right pursuant to Section 5.2(b), then upon expiration of the Option Period and thereafter until the expiration of the Term,
 
  
 (i) each Party shall share
with the other Party, and in any event Licensee shall require its Sublicensees to share with Coley (either directly or through Licensee), information regarding Immune Modulator Specifications as such Immune Modulator Specifications may be revised or
updated from time to time; 
  
 (ii)
the Parties shall consult with each other, and Licensee shall require its Sublicensees to consult with Coley and Licensee, prior to making any filing with the FDA or other Regulatory Authority related to the manufacture of Immune Modulators and/or
Licensed Products and/or making any submission for inclusion in a pharmacopoeia relating to Immune Modulators and/or Licensed Products, in each case to the extent the same could reasonably be expected to have any effect on Coley or its rights in or
to the Immune Modulator or the Technology; and  
  
 (iii) in the event that Licensee and/or any Sublicensee manufactures or has a third party manufacture Immune Modulator and uses information and/or intellectual property rights which result in a Regulatory Authority
mandating changes to any immunomodulatory oligonucleotide Specifications and, as a result, Coley is unable to obtain or manufacture reasonable quantities of Immune Modulator and/or other immunomodulatory oligonucleotides in compliance with the
mandate by such Regulatory Authority, Licensee shall, or shall cause its Sublicensees to (as the case may be), either, as determined by Licensee or Sublicensee, as the case may be, (1) provide Coley with a license on commercially reasonable terms to
the necessary information and/or intellectual property rights to manufacture the Immune Modulator and/or other immunomodulatory oligonucleotides in compliance with such immunomodulatory oligonucleotide Specifications or (2) manufacture or have
manufactured reasonable quantities of the Immune Modulator or such other immunomodulatory 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 21 

 
oligonucleotides for Coley in accordance with a supply agreement, and at a price and upon other terms and conditions, to be negotiated between the Parties.
Notwithstanding the foregoing, in the event Licensee or a Sublicensee has a third party manufacture Immune Modulator and/or other immunomodulatory oligonucleotides on its behalf, the obligations Licensee or such Sublicensee set forth in the
preceding sentence shall only apply to the extent the third party consents to such license (in the event the information and/or intellectual property is owned or controlled by such third party) and/or manufacturing obligations; provided,
however, that Licensee shall use, and shall cause its Sublicensee to use, commercially reasonable efforts to obtain such third party consent, including when negotiating future third party manufacturing agreements. 
  
 (d) During the exclusive period of the license granted to
Coley in the United States of America under the Iowa Agreement, any Licensed Product produced for sale in the United States of America shall, to the extent required by the Iowa Agreement, be manufactured substantially in the United States of America
unless a waiver of this requirement is obtained or this requirement otherwise ceases to apply. Coley shall, at Licensee’s request and expense, assist Licensee or any Sublicensee in attempting to obtain any such waiver should Licensee determine
to do so. 
  
 5.3 Marking. Licensee shall comply with the
requirements as to the marking of Licensed Products set forth in Article 7 of the Iowa Agreement. 
  

	6.	TERM AND TERMINATION. 

  
 6.1 Term. The term of this Agreement shall begin on the Effective Date and, unless earlier terminated pursuant to this Section 6, continue until
the later to occur of (i) the expiration or termination of the last Valid Claim of a Patent Right in the Territory or (ii) ten (10) years from the last First Commercial Sale of a Licensed Product in the Territory without another First Commercial
Sale of a Licensed Product in the Territory having occurred during such ten (10)-year period (the “Term”). 
  
 6.2 Termination. 
  
 (a) Termination by Either Party. Upon a material breach of this Agreement by either Party, the non-breaching Party may provide
written notice to the breaching Party specifying the material breach. If the breaching Party fails to cure the material breach during such sixty (60) day period following the date on which the notice of breach is provided, then the non-breaching
Party shall have the right to terminate this Agreement. If such breach is not reasonably cured within sixty (60) days but the breaching Party is making a bona fide effort to cure any such breach, such termination shall be delayed in order to permit
the breaching Party a reasonable period of time to remedy the breach. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 22 

 (b) Termination by Coley. 
  
 (i) Coley shall have the right upon written notice to
Licensee to terminate this Agreement for non-payment of any amount due hereunder from Licensee to Coley if such non-payment shall continue uncured for a period ending (1) thirty (30) days following notice of such non-payment given by Coley to
Licensee or, (2) if Licensee initiates a dispute resolution proceeding with respect to such payment prior to the expiration of such thirty (30) day period, then fifteen (15) days following the final conclusion of the dispute resolution proceeding.

  
 (ii) Coley may terminate this Agreement in
the event that Licensee challenges (1) the validity of the Patent Rights licensed to Licensee hereunder or, (2) in defense of or otherwise to defeat any claim made by Coley for royalties due pursuant to Section 3, the secrecy or substantiality of
the Know-How licensed to Licensee hereunder. In addition, in the event that any Sublicensee challenges the validity of the Patent Rights licensed to Licensee hereunder, Coley shall have the right to direct Licensee to terminate the sublicense
agreement with such Sublicensee by providing written notice to Licensee. In the event Licensee fails to terminate such sublicense agreement within thirty (30) days of receipt of such notice by Coley, Coley shall have the right to terminate this
Agreement immediately upon written notice to Licensee. 
  
 (iii) In addition, in the event that Coley becomes aware that a Sublicensee is in material breach of a sublicense agreement, Coley shall have the right to direct Licensee to terminate the sublicense agreement with such Sublicensee, by
providing written notice to Licensee, if the Sublicensee fails to cure the material breach during such sixty (60) day period following the date on which the notice of breach is provided; provided, however, that if the breaching
Sublicensee is making a bona fide effort to cure any such breach, such termination will be delayed in order to permit the breaching Sublicensee a reasonable period of time to remedy the breach. In the event Licensee fails to terminate such
sublicense agreement by (1) thirty (30) days following receipt of such notice by Coley (or such additional period as may be provided for the Sublicensee to cure the breach pursuant to the preceding sentence) or, (2) if Licensee or Sublicensee
initiates a dispute resolution proceeding with respect to such breach prior to the expiration of such thirty (30) day period, then fifteen (15) days following the final conclusion of the dispute resolution proceeding, Coley shall have the right to
terminate this Agreement immediately upon written notice to Licensee. 
  
 (c) Termination upon Elimination of All Specified Diseases. In the event that Licensee has exercised its rights under Section 1.2 (hhh) to delete from the definition of “Specified Diseases” all
Specified Diseases, this Agreement shall thereupon terminate without further action by either Party. 
  
 6.3 Effects of Expiration or Termination. 
  
 (a) Surviving Provisions. The provisions of Sections 2.3, 2.5, 3 (with respect to payment obligations accruing prior to the date of
expiration or termination), the second sentence of Section 3.4(c), 5.1, 7, 8, 9, 10, 11 and 12, and this Section 6.3 shall survive expiration or termination of this Agreement for any reason. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 23 

 (b) Licensee Rights. In addition to the provisions of Section 6.3(a), (i) upon
expiration of the Term or termination of this Agreement by Licensee pursuant to Section 6.2(a), the rights granted to Licensee pursuant to Section 2.1 shall become perpetual, irrevocable, fully paid-up and royalty-free, and (ii) upon termination of
this Agreement by Coley pursuant to Section 6.2(a) or (b) or upon termination of this Agreement pursuant to Section 6.2(c), Licensee shall have no further right to practice the Technology, and Licensee shall, at Coley’s election, promptly
return or destroy any unused Immune Modulator owned or Controlled by Coley or proprietary to Coley. Upon termination of this Agreement by Coley pursuant to Section 6.2(a) or (b), (i) Licensee and its Sublicensees shall have the right to exhaust
supplies of Licensed Products then in inventory and (ii) shall with respect to any sales of Licensed Products made prior to the termination of this Agreement or pursuant to clause (i) of this sentence, continue to provide Royalty Reports and to pay
royalties on all Net Sales of Licensed Products as required hereunder. 
  
 (c) Obligations Survive. Any termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to termination. 

 

	7.	CONFIDENTIALITY. 

  
 7.1 Nondisclosure Obligation. Each Party shall use the Confidential Information of the other Party only in accordance with the activities
contemplated by this Agreement and shall not disclose to any third party any Confidential Information of the other Party, without the prior written consent of the other Party. This obligation shall not apply to Confidential Information that:

  
 (a) is known by the Receiving Party at the
time of its receipt, and not through a prior disclosure by the Disclosing Party to the Receiving Party, as documented by business records; 
  
 (b) at the time of disclosure or thereafter becomes published or otherwise part of the public domain without breach of this Agreement by
the Receiving Party; 
  
 (c) is subsequently
disclosed to the Receiving Party by a third party who has the right to make such disclosure; or 
  
 (d) is developed by the Receiving Party independently of proprietary information or other information received from the Disclosing Party
and such independent development can be properly demonstrated by the Receiving Party. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 24 

 7.2 Permitted Disclosures. Notwithstanding the provisions of Section 7.1, a Receiving Party may
make the following disclosures of Confidential Information received from the Disclosing Party: 
  
 (a) disclosures to governmental or other regulatory agencies in order to obtain patents or to gain approval to conduct Licensed Product
trials or to market the Licensed Products, but such disclosure may be only to the extent reasonably necessary to obtain such patents or authorizations upon consultation with the other Party; 
  
 (b) disclosures to agents, consultants, Affiliates and/or
other third parties as necessary for the research and development, manufacturing and/or marketing of Licensed Products (or for such Persons to determine their interest in performing such activities) in accordance with this Agreement on the condition
that such third parties agree to be bound by the confidentiality obligations contained in this Agreement for a term of not less than ten (10) years; or 
  
 (c) disclosures required by law or court order, provided that notice is promptly delivered to the Disclosing Party in order to
provide it with an opportunity to seek a protective order or other similar order with respect to such proprietary information and the Receiving Party thereafter discloses only the minimum information required to be disclosed in order to comply with
the request, whether or not a protective order or other similar order is obtained by the Disclosing Party. 
  
 7.3 Partial Disclosures. It is agreed that specific portions of Confidential Information and/or data shall continue to be maintained in confidence
by the Parties in the event of a general disclosure of such Confidential Information and/or data. A combination of features in the Confidential Information and/or data shall continue to be maintained in confidence by the Parties hereunder unless
every feature of the Confidential Information and/or data has been disclosed in accordance with the provisions herein. 
  
 7.4 Publishing. 
  
 (a) The Parties shall mutually agree on procedures for publishing or presenting pre-clinical and clinical results achieved by Licensee
under this Agreement in scientific journals, at scientific meetings or in the general press. Neither Party shall submit, for written or oral publication, any manuscript, abstract, or the like that contains data, information or results arising from
this Agreement or, in the case of Licensee, otherwise relating to the Immune Modulator without first providing the other Party with a copy of the same at least thirty (30) days before such proposed submission date and obtaining the written consent
of the other Party, which consent shall not be unreasonably withheld or delayed. Nothing in this clause (a) shall qualify or limit the right of a Party to make such filings with Regulatory Authorities as may be required by law or necessary or
desirable to obtain Regulatory Approvals as contemplated herein. 
  
 (b) Notwithstanding the provisions of Section 7.4(a), the Parties acknowledge and agree that certain academic consultants may perform activities under this Agreement, and such academic consultants shall have the right
to publish or make public disclosures of the data resulting from their activities hereunder, subject to the provisions of this clause (b). Any academic consultant proposing to publish or make such public disclosure shall provide the Parties with a
draft of any such publication or disclosure by overnight mail or courier. The Parties shall have thirty (30) days from the date of receipt in which to review and comment upon 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 25 

 
such draft. If Coley and/or Licensee reasonably determines that the proposed publication or disclosure would disclose their respective Confidential
Information, such information shall be deleted from any proposed publication or disclosure. 
  
 7.5 Publicity. The Parties agree to issue an initial joint press release within a reasonable time after the execution of this Agreement. Such press release shall be substantially in the form as set forth in
Exhibit D. Thereafter, neither Coley nor Licensee (nor its Sublicensees) shall issue any press release or other public disclosure relating to this Agreement or any sublicense agreements without the prior written consent of the other Party,
which consent shall not be unreasonably withheld or delayed. Once any written statement is approved for disclosure by the Parties, either Party may make a subsequent public disclosure of the contents of such statement without further approval of the
other Party. Notwithstanding any other provision contained in this Section 7.5, either Party may make such public disclosure relating to this Agreement as may be required by applicable law. Prior to any public disclosure relating to this Agreement
pursuant to the preceding sentence, the Party proposing to make such disclosure shall provide reasonable notice thereof and the proposed contents of such disclosure to the other Party and shall consult in good faith with the other Party regarding
the timing and contents of any such disclosure. 
  
 7.6 Period
of Effectiveness. The provisions of this Section 7 shall terminate on the tenth anniversary of the termination or expiration of the Term. 
  

	8.	MAINTENANCE AND ENFORCEMENT OF PATENT RIGHTS. 

  
 8.1 Responsibility for Patent Rights. Coley, by counsel it selects, shall have the sole right, but not the obligation, to prepare, file, prosecute
and maintain all Patent Rights in Coley’s name and in countries designated by Coley at the sole discretion of Coley. In the event that Coley at any time elects not to 
  
 (a) pursue or continue the filing, prosecution (including any interferences, resisue and opposition
proceedings and re-examinations) or maintenance of any Patent Right in a particular country or 
  
 (b) seek any patent term extension, restoration or the like of any Patent Right in a particular country that may be available now or in
the future, then, in each such case, Coley shall notify Licensee in writing thereof not less than ninety (90) days before any deadlines by which an action must be taken to establish or preserve any such rights in such Patent Right in such country
and shall thereafter consult with Licensee in good faith as to what action, if any, should be taken with respect to the relevant Patent Right. 
  
 8.2 Infringement by Third Parties. Licensee agrees to provide, and shall cause its Sublicensees to provide, written notice to Coley promptly after
becoming aware of any infringement of the Patent Rights. Coley shall have the right, but not the obligation, under its own control and at its own expense, to prosecute any third party infringement of the Patent Rights and/or to defend the Patent
Rights in any declaratory judgment action brought by a Third  

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 26 

 
Party which alleges invalidity, unenforceability, or non-infringement of the Patent Rights. Coley may enter into any settlement, consent judgment, or other
voluntary final disposition of any infringement or declaratory judgment action hereunder without the prior written consent of Licensee. If Coley decides not to bring suit for infringement in the Field under the relevant Patent Rights, Coley shall
notify Licensee reasonably in advance of any deadline for such enforcement and Licensee shall have the right to bring suit on its own behalf, at its sole cost and expense. Coley shall have a continuing right to intervene in such suit. Subject to the
provisions of the next sentence, Licensee shall take no action to compel Coley either to initiate or to join in any such suit for patent infringement. At Licensee’s request, Coley shall initiate or join in any such suit if necessary to avoid
dismissal of the suit; in such event, Licensee shall reimburse Coley for its reasonable attorney’s fees and costs.  
  
 8.3 Infringement Claims. If the manufacture, sale or use of a Licensed Product in the Field results in any claim, suit or proceeding filed by a
third party alleging patent infringement by Coley or Licensee, such Party shall promptly notify the other Party in writing. In the event that one Party is sued, the Party subject to such claim shall have the exclusive right to defend and control the
defense of any such claim, suit or proceeding, at its own expense, using counsel of its own choice; provided, however, that Coley may participate in the defense of such claim defended by Licensee through counsel of Coley’s own
choosing and at Coley’s own expense, and provided, further, that Licensee shall not enter into any settlement which admits or concedes that any aspect of the Patent Rights is invalid or unenforceable without the prior written
consent of Coley, which consent shall not be unreasonably withheld or delayed. The Party subject to the claim shall keep the other Party hereto reasonably informed of all material developments in connection with any such claim, suit or proceeding.
The Party not subject to the claim shall cooperate in all reasonable respects with the Party subject to the claim in the defense of the claim. Licensee shall cause its Sublicensees to be bound to this provision to the same extent Licensee is so
bound. 
  
 8.4 Settlements. No settlements, consent
judgments, or other voluntary final dispositions of a dispute adversely affecting the rights or obligations of a Party, including the rights or obligations of the Party under this Agreement, shall be entered into in connection with any dispute,
claim or proceeding described in Section 8.2 or 8.3 without the prior written consent of the adversely affected Party, such consent not to be unreasonably withheld or delayed. Without limiting the foregoing, no settlements, consent judgments, or
other voluntary final dispositions of any dispute, claim or proceeding described in Section 8.2 or 8.3 adversely affecting the rights or obligations of Coley under the Patent Rights shall be entered into without the prior written consent of Coley,
such consent not to be unreasonably withheld or delayed. The Parties shall comply with the provisions of Section 8.4 of the Iowa Agreement with respect to any settlement, consent judgment, or other voluntary final disposition of any suit relating to
the subject matter of this Agreement. 
  
 8.5 Recoveries
and Damages. Any recoveries and damages received as a result of a dispute, claim or proceeding described in Section 8.2 or 8.3 or any settlement, consent judgment, or other voluntary final disposition thereof shall first go toward reimbursing
the Parties for their respective costs and expenses of such suit. Thereafter, all remaining recoveries not otherwise expressly allocated between the Parties in connection with the final disposition of the dispute 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 27 

 
shall be allocated [**********] percent ([**]%) to Coley and [************] percent ([**]%) to Licensee. 
  
 8.6 Subject to Iowa Agreement. The provisions of this Section 8 are
subject to in all respects the provisions of the Iowa Agreement, including Article 8 thereof. 
  

	9.	REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PARTIES. 

  
 9.1 Representations and Warranties of Each Party to the Other. Each Party hereby represents and warrants to the other Party hereto, effective as of
the Effective Date, that: 
  
 (a) Such Party is a
corporation duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation or formation; 
  
 (b) The execution and performance of this Agreement by such Party has been duly authorized by all requisite corporate action; 

 
 (c) Such Party has the power and authority to execute and
deliver this Agreement and to perform its obligations hereunder, including the right, power and authority to grant the licenses granted herein; 
  
 (d) The execution and performance by such Party of this Agreement and its compliance with the terms and provisions hereof does not and, to
its knowledge, will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) any loan agreement, guaranty, financing agreement, agreement affecting a Licensed Product or the Immune Modulator, or
other agreement or instrument binding or affecting it or its property; (ii) the provisions of its charter documents or bylaws; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which it or
any of its property is bound; 
  
 (e) The
execution and performance by such Party of this Agreement and its compliance with the terms and provisions hereof do not and, to its knowledge, will not violate any law, rule or regulation applicable to it; and 
  
 (f) This Agreement has been duly authorized by all necessary
corporate action on the part of such Party, has been executed and delivered by such Party and constitutes such Party’s legal, valid and binding obligation, enforceable against such Party in accordance with its terms subject, as to enforcement,
to bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting creditors’ rights and to the availability of particular remedies under general equity principles. 
  
 9.2 Covenants of Licensee. Licensee hereby covenants with Coley that:

  
 (a) Licensee will not use the Immune
Modulator or any Coley Confidential Information or Know-How for any purpose other than as contemplated under this Agreement; 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 28 

 (b) It will comply with all laws and regulations applicable to the use, storage,
disposal, and transfer of Immune Modulator; and 
  
 (c) It will comply with all of the obligations applicable to sublicensees of Coley under the Iowa Agreement. 
  
 (d) Licensee will not, and will not permit its Sublicensees, to market or actively promote any Licensed Product for off-label use outside
the Field; provided, however, that the provisions of this clause (d) are not intended, and shall not be construed, to limit the right of Licensee or any Sublicensee to respond to requests from medical professionals and other
appropriate Persons for information regarding the off-label use of the Licensed Product. 
  
 9.3 Representations and Warranties of Coley. Coley hereby represents and warrants to Licensee, effective as of the Effective Date, that: 
  
 (a) Coley owns or possesses adequate licenses or other rights to use the Technology in the Field and to
grant the rights and licenses herein; 
  
 (b) To
its knowledge, the granting of the rights and licenses herein to Licensee does not violate any right of any third party; 
  
 (c) Coley has not received notice that it is in breach of its obligations under the Iowa Agreement and there is no basis for a valid claim
that it is in breach of its obligations under the Iowa Agreement; 
  
 (d) No term or provision of this Agreement constitutes or gives rise to, or will constitute or give rise to, a breach of the Iowa Agreement; and 
  
 (e) (i) To its knowledge, the Patent Rights have not been held by a court of competent jurisdiction to be
invalid or unenforceable, in whole or in part; (ii) it has not received notice of any claim or litigation by any Person alleging that any Patent Right is invalid or unenforceable; (iii) to its knowledge, the conception, development and reduction to
practice of the Technology existing as of the Effective Date have not constituted or involved the misappropriation of trade secrets or other rights or property of any Person; and (iv) it has not received notice of any claim or litigation asserted or
commenced against it or any of its Affiliates that would have an adverse effect on the rights granted to Licensee under this Agreement. 
  
 9.4 Bayh-Dole. Both Parties acknowledge that the U.S. Public Health Service may have certain rights, as provided in Bayh-Dole (Public Law 96-517 of
1980), to the Patent Rights. 
  

	10.	INDEMNIFICATION AND LIMITATION OF LIABILITY. 

  
 10.1 Indemnification by Licensee. Licensee shall indemnify, defend and hold harmless Coley and its Affiliates, and each of its and their respective
employees, officers, directors and agents (each, a “Coley Indemnified Party”), from and against any and all liability, 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 29 

 
loss, damage, cost, and expense, including reasonable attorneys’ fees and reasonable expenses of litigation (collectively, a “Liability”),
arising out of any third party claim which the Coley Indemnified Party may incur, suffer or be required to pay to the extent resulting from or arising in connection with (i) the breach by Licensee of any covenant, representation or warranty
contained in this Agreement; (ii) any negligent or wrongful act or omission of Licensee (or any of its Affiliates or Sublicensees, or their respective directors, officers, or agents, or distributors thereof) which is the proximate cause of injury,
death or property damage to a third party; (iii) actual or asserted violations of any applicable law or regulation by Licensee, its Affiliates, Sublicensees, or distributors by virtue of which Licensed Products in the Field manufactured, distributed
or sold by Licensee, its Affiliates, Sublicensees, or distributors shall be alleged or determined to be adulterated, misbranded, mislabeled or otherwise not in compliance with any applicable law or regulation; (iv) claims for bodily injury, death,
product liability, warranty of fitness or merchantability, or property damage attributable to the development, manufacture, distribution, sale or use of Licensed Products in the Field by Licensee, its Affiliates, Sublicensees, or distributors; or
(v) a recall of Licensed Products in the Field manufactured, distributed or sold by Licensee, its Affiliates, Sublicensees, or distributors ordered by a governmental agency or required by a confirmed product failure as reasonably determined by
Licensee, its Affiliates, Sublicensees, or distributors; except, in the case of clauses (ii) through (v), to the extent that such Liability arises in connection with or is otherwise attributable to a breach by Coley of this Agreement or any
manufacturing agreement into which Coley may enter pursuant to Section 5.2 or any negligent or wrongful act or omission on the part of Coley or its Affiliates. 
  

10.2 Indemnification by Coley. Coley and its Affiliates shall indemnify, defend and hold harmless Licensee and its employees, officers,
directors and agents (each, an “Licensee Indemnified Party”) from and against any Liability arising out of any third party claim which the Licensee Indemnified Party may incur, suffer or be required to pay to the extent resulting from or
arising in connection with (i) the breach by Coley of this Agreement (including its obligations with respect to the production, shipment, validation and release of Immune Modulator under Section 5.2(a)) or any manufacturing agreement into which
Coley may enter pursuant to Section 5.2(b); or (ii) any negligent or wrongful act or omission by Coley (or any of its Affiliates or their respective directors, officers, or agents, or distributors thereof) which is the proximate cause of injury,
death or property damage to a third party; except, in the case of clause (ii) to the extent that such Liability arises in connection with or is otherwise attributable to a breach by Licensee of this Agreement or any negligent or wrongful act or
omission on the part of Licensee or its Affiliates or Sublicensees. 
  
 10.3 Indemnification Procedure. Any Person seeking indemnification under this Section 10 (the “Indemnitee”) shall promptly notify the Party from whom indemnification is sought (the “Indemnitor”) in writing of any
Claim, and the Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so desires, to assume the defense thereof with counsel mutually satisfactory (consent not to be unreasonably withheld or delayed) to the other Party
by giving written notice to the Indemnitee and the other Party within thirty (30) days after receipt of written notice of such Claim from the Indemnitee; provided, however, that an Indemnitee shall have the right to retain its own
counsel, with the fees and expenses to be paid (a) by the Indemnitor, if representation of such Indemnitee by the counsel retained by the 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 30 

 
Indemnitor would be inappropriate due to actual or potential differing interests between the Indemnitee and any other party represented by such counsel in
such proceeding; or (b) by Indemnitee in all other cases. In no event shall the Indemnitor be liable for any Liabilities that result from any delay by the Indemnitee in providing the written notice pursuant to the first sentence of this Section
10.3. In the event that it is ultimately determined that the Indemnitor is not obligated to indemnify, defend or hold harmless an Indemnitee from and against such Claim, the Indemnitee shall reimburse the Indemnitor for any and all costs and
expenses (including attorneys’ fees and costs of suit) and any Liabilities incurred by the Indemnitor in its defense of such Claim with respect to the Indemnitee. The Indemnitee and the other Party, and its employees and agents, shall
reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any Claim covered by this Section 10. 
  
 10.4 Settlements. Neither Party may settle a Claim without the consent of the other Party if such settlement would (a) impose any monetary
obligation on the other Party, (b) require the other Party to submit to an injunction, or (c) otherwise limit the other Party’s rights under this Agreement, such consent not to be unreasonably withheld or delayed in the case of clauses (b) and
(c). Any payment made by a Party to settle a Claim shall, unless otherwise provided in Section 10.1 or 10.2, as the case may be, be at its own cost and expense. 
  

10.5 Limitation of Liability. With respect to any claim by one Party against the other Party arising out of the performance or failure of
performance of the other Party under this Agreement, the Parties expressly agree that, except for a Party’s indemnification obligations pursuant to Section 10.1 or 10.2 with respect to third party claims, the liability of such Party to the
other Party for such breach shall be limited under this Agreement or otherwise at law or equity to direct damages only and in no event shall a Party be liable for punitive, exemplary or consequential damages. 
  
 10.6 Insurance. 
  
 (a) Licensee. Prior to or immediately upon the first
administration of any Licensed Product in the Field to a human in accordance with this Agreement, and for a period of five (5) years after the last sale of any Licensed Product in the Field hereunder, Licensee shall obtain and/or maintain, and shall
require its Sublicensees to obtain and/or maintain, at its expense, product liability insurance in amounts which are reasonable and customary in the industry for companies of comparable size and activities. Such product liability insurance shall
insure against liability for personal injury, physical injury, and property damage. Licensee shall provide proof of insurance to Coley upon request. Licensee may satisfy this requirement by a representation that it is self-insured and/or maintains
third party liability insurance in amounts sufficient to meet the foregoing requirement. 
  
 (b) Coley. Prior to or immediately upon the first administration of any Licensed Product in the Field to a human in accordance with
this Agreement, as notified by Licensee to Coley, and for a period of five (5) years after the last sale of any Licensed Product in the Field hereunder, as notified by Licensee to Coley, Coley shall obtain and/or maintain, at its expense, product
liability insurance in amounts which are reasonable and customary in the industry for companies of comparable size and activities. Such product liability insurance shall insure 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 31 

 
against liability for personal injury, physical injury, and property damage. Coley shall provide proof of insurance to Licensee upon request. Coley may
satisfy this requirement by a representation that it is self-insured and/or maintains third party liability insurance in amounts sufficient to meet the foregoing requirement. 
  
 10.7 Warranty Disclaimer. EXCEPT AS EXPRESSLY MADE UNDER THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS, NOR
EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT, WITH RESPECT, IN THE CASE OF COLEY, TO THE IMMUNE MODULATOR OR OTHER
IMMUNOMODULATORY OLIGONUCLEOTIDES FURNISHED TO LICENSEE OR, IN THE CASE OF BOTH PARTIES, TO ANY PATENT RIGHTS, KNOW-HOW, PRODUCT, INVENTION, TECHNOLOGY, SERVICES, GOODS OR OTHER SUBJECT MATTER OF THIS AGREEMENT. 
  

	11.	REPORTING OF SAFETY AND OTHER DATA.  

  
 11.1 Safety Data. 
  
 (a) Licensee shall report to Coley, and shall require its Sublicensees to report to Coley, safety data and any possible adverse
events associated with Licensed Products pursuant to the provisions of the safety procedures reasonably acceptable to Licensee which shall be delivered by Coley to Licensee within a reasonable period of time after the Effective Date. 
  
 (b) Coley shall treat information disclosed to it pursuant
to this Section 11.1 as Confidential Information with the following exceptions: 
  
 (i) Coley will use this data to generate a document reporting any trends seen in Licensed Products that may be related to the Immune
Modulator. Coley shall have the right to share this update with Licensee and other licensees that incorporate Immune Modulator into products. 
  
 (ii) Coley will be free to use such information in communications with the FDA or any other Regulatory Authorities; provided,
however, that no communication shall be made by Coley with the FDA or other Regulatory Authorities in reliance on the provisions of this clause (ii) that could adversely affect a Licensed Product without the consent of Licensee, which consent
shall not be unreasonably withheld or delayed. 
  
 It is understood that the
proviso clause of clause (ii) is not intended, and shall not be construed, to in any way qualify or limit the right of Coley to make disclosures of Confidential Information permitted by Section 7.2. 
  
 11.2 Preclinical and Clinical Data. Licensee shall report to Coley,
and shall require its Sublicensees to report to Coley, any and all preclinical and clinical data resulting from the 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 32 

 
testing of Immune Modulator alone. This will include, but will not be limited to, toxicology study results. All such information shall constitute
Confidential Information. 
  
 11.3 Coley Reports.
Coley shall promptly provide Licensee with any reports produced by Coley pursuant to Section 11.1(b)(i) and with updates summarizing data from studies of Immune Modulator when used alone as well as reporting trends in products that contain the
Immune Modulator that may be related to Immune Modulator. 
  
 11.4 Other Licensees. Coley shall secure from all other Persons to whom it may grant licenses or other rights with respect to the Immune Modulator legally binding commitments similar to those set forth in this Section 11 relating to
the disclosure of information relating to the Immune Modulator and all such rights as Coley may require in order to make the disclosures to Licensee contemplated by this Section 11. 
  

	12.	MISCELLANEOUS. 

  
 12.1 Assignment. Neither this Agreement nor any or all of the rights and obligations of a Party shall be assigned, delegated, sold, transferred,
sublicensed (except as otherwise provided herein) or otherwise disposed of, by operation of law or otherwise, to any third party without the prior written consent of the other Party, which shall not be unreasonably withheld, and any attempted
assignment, delegation, sale, transfer, sublicense or other disposition, by operation of law or otherwise, of this Agreement or of any rights or obligations hereunder contrary to this Agreement shall be a material breach of this Agreement by the
attempting Party and shall be void and without force or effect; provided, however, that either Party may, without such consent, assign the Agreement and its rights and obligations hereunder in connection with the transfer or sale of
all or substantially all of its assets or stock, in the event of its merger or consolidation or change in control or similar transaction, or, in the case of Licensee, in the event of a sale or transfer by Licensee of all or substantially all of its
vaccine business related to vaccines targeting one or more of the Specified Diseases or, on a Licensed Product-by-Licensed Product basis, in connection with the transfer or sale of all or substantially all of its business related to a Licensed
Product. In addition, either Party may, without such consent, assign the Agreement and delegate its rights and obligations hereunder, in whole or in part, to an Affiliate; provided, however, that the Party making any such assignment or
delegations shall, notwithstanding such assignment or delegation, remain responsible for the full, complete and faithful performance of its obligations hereunder. This Agreement shall be binding upon, and inure to the benefit of, each Party, and its
permitted successors and assigns. 
  
 12.2 Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, U.S.A. without regard to its conflict of law rules. 
  
 12.3 Arbitration. Any dispute, controversy or claim arising out of or relating to this Agreement, or the breach
thereof, including any question regarding this Agreement’s existence, termination or validity, shall be referred to and finally settled by binding arbitration, in 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 33 

 
accordance with the rules of the American Arbitration Association in force on the date the demand for arbitration is filed. The demand for arbitration may be
filed by either Party within a reasonable time after the controversy or claim has arisen, but no later than after the date upon which institution of legal proceedings shall be barred by the applicable statute of limitations. There shall be three (3)
arbitrators, each Party to designate one arbitrator and the two Party-designated arbitrators to select the third arbitrator. The Party initiating recourse to arbitration shall include in its notice of arbitration its appointment of an arbitrator.
The place of arbitration shall be Boston, Massachusetts. The language to be used in the arbitral proceedings shall be English. Any determination by such arbitration shall be final and conclusively binding. Judgment on the arbitral award may be
entered in any court having jurisdiction thereof. All costs incurred in connection with such arbitration, including reasonable attorneys’ fees, shall be borne by the Party which incurs the costs; provided that a Party which is determined by the
arbitral tribunal to have been in willful default of the provisions of this Agreement shall bear all costs of arbitration. 
  
 12.4 Injunctive Relief and Jurisdiction. Nothing in this Agreement shall be construed to limit or preclude a Party from bringing any action in any
court of competent jurisdiction for injunctive or other provisional relief to compel the other Party to comply with its obligations hereunder, whether before or during the pendancy of arbitration proceedings. The Parties agree that all such suits
may, at the option of either Party, be initiated and maintained before the United States District Court for the District of Massachusetts, U.S.A. and both Parties submit to personal jurisdiction and to the service of process, pleadings and notices
in connection with any and all actions seeking such injunctive or provisional relief to the court referred to above. Notwithstanding the foregoing, any dispute regarding the validity, scope or enforceability of patents, trademarks or other
intellectual property that is or can be the subject of registration with a governmental entity shall be submitted to a court of competent jurisdiction in the territory in which such rights apply. 
  
 12.5 Waiver. Any delay or failure in enforcing a Party’s rights
under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, nor operate to bar the exercise or enforcement
thereof at any time or times thereafter, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time. No waiver of a breach shall be deemed to be a waiver of a different or subsequent breach.

  
 12.6 Independent Relationship. Nothing herein contained
shall be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or
failure to act of the other Party. Neither Party shall have any power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.

  
 12.7 Export Control. This Agreement is made subject to
any restrictions concerning the export of Licensed Product or technical information from the United States of America which may be imposed upon or related to the Parties from time to time by the government of the United 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 34 

 
States of America. Licensee agrees that it will not export, directly or indirectly, any technical information acquired from Coley under this Agreement, and
Licensee agrees that it will not export, directly or indirectly, any Licensed Product using such technical information, to any country for which the United States government or any agency thereof at the time of export requires an export license or
other governmental approval, without first obtaining any consent that may be required by applicable law, rule or regulation. 
  
 12.8 Entire Agreement; Amendment. This Agreement sets forth the complete, final and entire agreement of the Parties relating to the subject matter
hereof and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties with respect thereto and supersedes and terminates all prior agreements, writings and understandings between the
Parties to the extent they relate to the subject matter hereof. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties relating to the subject matter
hereof other than as are set forth herein or otherwise contemplated by this Section 12.8. No terms or provisions of this Agreement shall be varied or modified and no subsequent alteration, amendment, change or addition to this Agreement shall be
binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 
  
 12.9 Notices. Each notice required or permitted to be given or sent under this Agreement shall be in writing and delivered personally or given by
facsimile transmission (with confirmation copy by registered first-class mail) or by registered or certified mail (return receipt requested) or overnight courier, to the Parties at the addresses and facsimile numbers indicated below. 
  

			
	 If to Coley, to:
	  	Coley Pharmaceutical Group, Inc.
	 	  	Wellesley Gateway
	 	  	93 Worcester Street, Suite 101
	 	  	Wellesley, MA 02481, U.S.A.
	 	  	Attention: President and CEO
	 	  	Facsimile: 1-781-431-6403
		
	 with a copy to:
	  	Coley Pharmaceutical Group, Inc.
	 	  	Wellesley Gateway
	 	  	93 Worcester Street, Suite 101
	 	  	Wellesley, MA 02481, U.S.A.
	 	  	Attention: Vice President and General Counsel
	 	  	Facsimile: 1-781-431-6403
		
	 If to Licensee, to:
	  	Chiron Srl
	 	  	Via Fiorentina 1,
		
	 	  	 53100 Siena, Italy
  
 Attention: Riccardo Manetti, PhD

	 	  	Director Business Development, Emerging Opportunities
	 	  	Facsimile: + 39 0577 243476

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 35 

			
	 with a copy to:
	  	Chiron Corporation
	 	  	4560 Horton Street
	 	  	Emeryville, CA 94608
	 	  	Attention: Corporate Counsel
	 	  	Facsimile: +1 510 654 5360

  
 All notices, requests, reports,
approvals or other communications required or permitted under this Agreement shall be in writing (except in the case of verbal communications and teleconferences updating either Party as to the status of work hereunder), and shall be deemed given
(a) when delivered personally; (b) ten (10) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (c) one (1) day after deposited with a commercial express courier specifying next day delivery,
with written verification of receipt. Either Party may change its address or its facsimile number by giving the other Party written notice, delivered in accordance with this Section. 
  
 12.10 Force Majeure. Failure of any Party to perform its obligations under this Agreement (except the obligation to
make payments when properly due) shall not subject such Party to any liability or place them in breach of any term or condition of this Agreement to the other Party if such failure is caused by any cause beyond the reasonable control of such
non-performing Party, including acts of God, fire, explosion, flood, drought, war (whether or not declared), terrorism, riot, sabotage, embargo, strikes or other labor trouble, failure in whole or in part of suppliers to deliver on schedule
materials, equipment or machinery, interruption of or delay in transportation, a national health emergency or compliance with any order or regulation of any government entity acting with color of right; provided, however, that the
Party affected shall promptly notify the other Party of the condition constituting force majeure as defined herein and shall exert reasonable efforts to eliminate, cure and overcome any such causes and to resume performance of its obligations with
all possible speed. If a condition constituting force majeure as defined herein exists for more than ninety (90) consecutive days, the Parties shall meet to negotiate a mutually satisfactory solution to the problem, if practicable. 
  
 12.11 Severability. If any provision of this Agreement is declared
invalid or unenforceable by a court having competent jurisdiction, it is mutually agreed that, except to the extent that either Party would be adversely affected thereby, this Agreement shall endure except for the part declared invalid or
unenforceable by order of such court; provided, however, that in the event that the terms and conditions of this Agreement are materially altered, the Parties will, in good faith, renegotiate the terms and conditions of this Agreement
to reasonably substitute a valid and enforceable provision consistent with the intent of this Agreement for such invalid or unenforceable provision. 
  
 12.12 Recording. Subject to the provisions of Section 7, each Party shall have the right, at any time, to record, register, or otherwise notify
this Agreement in appropriate 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 36 

 
governmental or regulatory offices anywhere in the Territory, and each Party shall provide reasonable assistance to the other Party in effecting any such
recording, registering or notifying. 
  
 12.13 Further
Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
  
 12.14 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original as against either Party whose signature appears thereon, but all of which taken together shall constitute but one and the same instrument. Copies of executed counterparts of this Agreement transmitted
by facsimile shall be considered original executed counterparts provided receipt of such facsimile is confirmed. 
  
 12.15 Iowa Agreement. In the event that the license granted to Coley under the Iowa Agreement terminates for any reason, (a) this Agreement shall
continue, provided that Licensee agrees in writing that UIRF is entitled to enforce the Iowa Agreement directly against Licensee and (b) Licensee shall have the right, without any obligation or liability to Coley of any kind, to deal directly with
UIRF with respect to the subject matter of this Agreement. 
  
 [The
remainder of this page was left blank intentionally.] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 37 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.

  

									
	Coley Pharmaceutical Group, Inc.	 	 	 	Chiron Corporation
					
	 By:
	 	 /s/ Robert L. Bratzler
	 	 	 	 By:
	 	 /s/ John Lambert

					
	 Title:
	 	 President & CEO
	 	 	 	 Title:
	 	 President

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
 38 

  
 EXHIBIT A 

 
 Iowa Agreement 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

  
 EXHIBIT B 

 
 Licensee’s Existing IP 
  
 [***********] 
 [***********] 
 [***********] 
 [***********] 
 [***********] 
 [***********]

 [************] 
 [************] 
  
 [********************************************] 
 [*****************************] 
 [**************] 
 [*****************************] 
 [*****************************] 

[*****************************] 
 [*****************************]

 [*******************************************************************************************] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

  
 EXHIBIT
C 
  
 Patent Rights 
  
 Patents Claiming Priority to Patent Application Serial No. [**********] filed [**********]

  

													
	 WGS #

	  	 SN

	  	 FILING
 DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

							
	 [************]
	  	[***********]	  	[********]	  	 [*****]
 [********]
 [*********]
	  	 [****]
 [***]
 [*******]
	  	 [****************
 ****************]
	  	 Issued US 6,194,388 B1
 02-27-2001

(CIP of 08/276,358)

							
	 [************]
	  	 [*************
 **************]
	  	[********]	  	 [*****]
 [********]
 [*********]
	  	 [****]
 [***]
 [*******]
	  	 [*******************
 *************]
	  	 National Stage
 Published 02/01/96

							
	 [***********
 ********]
	  	 [**************
 ****
 **************
 ***************
 ****
 **************]
	  	[********]	  	 [*****]
 [********]
 [*********]
	  	 [****]
 [***]
 [*******]
	  	 [*******************
 *************]
	  	 Granted Patent No. 713040
 Pending
 Pending
 Pending

							
	 [************]
	  	[******************]	  	[********]	  	 [*****]
 [********]
 [*********]
	  	 [****]
 [***]
 [*******]
	  	 [******************
 **************]
	  	 Allowed
 Divisional of
Australia 713040

							
	 [************]
 [************]
 [************]
	  	 [*************]
 [*************]
 [*************]
	  	[********]	  	 [*****]
 [********]
 [*********]
	  	 [****]
 [***]
 [*******]
	  	 [******************
 **************]
	  	 Pending
 Divisional of Europe
95911630.2

							
	 [**********]
	  	[***********]	  	[********]	  	 [*****]
 [*****]
 [*******]
 [*********]
	  	 [****]
 [***]
 [***]
 [*******]
	  	 [*******************
 ******************]
	  	 Issued 6,207,646 B1
 03-27-2001
 (CIP of US 6,194,388, C1039/7001)

							
	 [**********]
	  	[*************]	  	[********]	  	 [*****]
 [********]
 [*********]
	  	 [****]
 [***]
 [*******]
	  	 [*******************
 ******************]
	  	 Issued US 6,239,116 B1
 05-29-01
 (CIP of US 6,207,646 B1, C1039/7004)

							
	 [*************]
	  	 [*****************
 **********]
	  	[********]	  	 [*****]
 [*****]
 [*******]
 [*********]
	  	 [****]
 [***]
 [***]
 [*******]
	  	 [*******************
 **************
****]
	  	 Entered National Phase 04/14/99
 Published
05/07/98

							
	 [************ *************
 *********]
	  	 [**************
 ***************
 ***************
 ***************
 ***************
 ***************
 ***************
 ***************
 ***************
 ***************
 ****]
	  	 [********]
 [********]
 [********]
 [********]
 [********]
 [********]
 [********]
 [********]
	  	 [*****]
 [*****]
 [*******] [*********]
 [*******]
	  	 [****]
 [****]
 [***]
 [***]
 [*******]
	  	 [*******************
 ******************]
	  	 Pending
  
 Pending
 Pending
 Pending
 Pending
 Allowed 335397-03/08/01
 Allowed 12/06/00
 Pending

							
	 [**********]
	  	[**************]	  	[********]	  	 [*****]
 [********]
 [*********]
	  	 [****]
 [***]
 [*******]
	  	 [****************
 ****************]
	  	 ABN in favor of C1039.7083
 DIV of
7001

							
	 [**********]
	  	[***********]	  	[********]	  	 [*****]
 [********]
 [*********]
	  	 [****]
 [***]
 [*******]
	  	 [*****************
 ***************]
	  	 Pending
 CON of 09/415,142
 (C1039/7029)

							
	 [**********]
	  	[***********]	  	[********]	  	 [*****]
 [********]
 [*********]
	  	 [****]
 [***]
 [*******]
	  	 [****************
 *****************
 **************]
	  	 ABN in favor of 7084
 CIP of US
 09/415,142,
 C1039/7029

													
	 WGS #

	  	 SN

	  	 FILING
 DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [**********]
	  	[***********]	  	 [******
 **]
	  	 [*****]
 [********]
 [*********]
	  	 [****]
 [***]
 [*******]
	  	 [*******************
 ********************
 *]
	  	 Pending
 CON of US
 09/931,583,
 C1039/7053

							
	 [**********]
	  	[***********]	  	 [******
 **]
	  	 [*****]
 [********]
 [*********]
	  	 [****]
 [***]
 [*******]
	  	 [******************
 *****************
 ******************]
	  	 Pending CON of US
 6,239,116,

C1039/7005

							
	 [**********]
	  	[***********]	  	 [******
 **]
	  	 [*****]
 [********]
 [*********]
	  	 [****]
 [***]
 [*******]
	  	 [*******************
 *****************]
	  	 ABN in favor of 7077
 CON of
US
 6,239,116
 C1039/7005

							
	 [**********]
	  	[***********]	  	 [******
 **]
	  	 [*****]
 [********]
 [*********]
	  	 [****]
 [***]
 [*******]
	  	 [****************
 ********************]
	  	 Pending CON of US
 09/337,893,

C1039/7021

  
 [********************************************] 
  

													
	 WGS #

	  	 SN

	  	 FILING
 DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [************]
	  	 [***************]
 [***********]
	  	 [******
 **]
	  	 [*****]
 [*****]
 [*****]
 [*******]
 [*********]
	  	 [****]
 [*******]
 [****]
 [***]
	  	 [*******************
 *******************
 *******************
 *********]
	  	 Entered National Phase 8/18/99
 Published
09/17/98

							
	 [***************
 *******]
	  	 [***************
 **]
 [**************]
 [***************
 ****]
 [*************]
	  	 [******
 **]
 [******
 **]
 [******
 **]
 [******
 **]
	  	 [*****]
 [*****]
 [*****]
 [*******]
 [*********]
	  	 [****]
 [*******]
 [****]
 [***
	  	 [*******************
 *******************
 *******************
 *********]
	  	 Pending
 Pending
 Pending
 Pending

							
	 [**********]
	  	[**************]	  	 [******
 **]
	  	 [*****]
 [*****]
 [*****]
	  	 [****]
 [*******]
 [****]
	  	 [*******************
 *******************
 *******************
 *********]
	  	Issued US 6,406,705 B1 (CIP of PCT/US98/04703, C1039/7006WO)
							
	 [**********]
	  	[**************]	  	 [******
 **]
	  	 [*****]
 [*****]
 [*****]
	  	 [****]
 [*******]
 [****]
	  	 [*******************
 *******************
 *******************
 *********]
	  	 Pending, Divisional of US 09/325,193
 (CON of US
6,406,705 B1, C1039/7025)

  
 [********************************************] 
  

													
	 WGS #

	  	 SN

	  	 FILING
 DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [**********]
	  	[**************]	  	 [******
 **]
	  	 [*****]
 [********]
	  	 [****]
 [****]
	  	 [*******************
 *******************
 *******************
 *********]
	  	Issued
							
	 [**********]
	  	[**************]	  	 [******
 **]
	  	 [*****]
 [********]
	  	 [****]
 [****]
	  	 [*******************
 *******************
 *******************
 *********]
	  	 Pending
 Divisional of US 09/191,170,
 C1039/7017

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 [*********************************************************************** 
 *************************] 

													
	 WGS #

	  	 SN

	  	 FILING DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [**********]
	  	[**************]	  	 [******
 **]
	  	 [**********]
 [******]
	  	 [*******]
 [*******]
	  	 [*******************
 ********************
 *****************]
	  	Issued US 5,663,153 (CIP of US 08/217,988)
	 [**********]
	  	[**************]	  	 [******
 **]
	  	 [**********]
 [******]
	  	 [*******]
 [*******]
	  	 [*******************
 ********************
 *****************]
	  	Issued US 5,723,335 03-03-98 (CON of US 08/217,988)
	 [**********]
	  	[**************]	  	 [******
 **]
	  	 [**********]
 [******]
	  	 [*******]
 [*******]
	  	 [*******************
 ********************
 *****************]
	  	Allowed (CON of US 5,723,335 C1037/7015)
	 [**********]
	  	 	  	 	  	 [**********]
 [******]
	  	 [*******]
 [*******]
	  	 [*******************
 ********************
 *****************]
	  	Pending (CON of US 09/009,634, C1037/7016)

  
 [************************************]

													
	 WGS #

	  	 SN

	  	 FILING DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [**********]
	  	[**************]	  	 [******
 **]
	  	 [*****]
 [******]
	  	 [****]
 [****]
	  	 [******************
 *******************
 *******************
 *******************
 *******************
 ***************]
	  	 Issued 6,218,371 B1
 04-17-2001

	 [************]
	  	 [***************
 ************]
	  	 [******
 **]
	  	 [*****]
 [******]
	  	 [****]
 [****]
	  	 [******************
 *******************
 *******************
 *******************
 *******************
 ***************]
	  	 Entered National Stage
 Published
10/14/99

	 [*************
 ********]
	  	 [***************
 ****]
 [**************]
 [***************
 ***]
 [*********
 ***********]
 [***************
 **]
	  	 [******
 **]
	  	 [*****]
 [******]
	  	 [****]
 [****]
	  	 [******************
 *******************
 *******************
 *******************
 *******************
 ***************]
	  	 Pending
 Pending
 Published 01/17/01 EP 1067956
 Pending
  
 Pending

	 [**********]
	  	[**************]	  	 [******
 **]
	  	 [*****]
 [******]
	  	 [****]
 [****]
	  	 [******************
 *******************
 *******************
 *******************
 *******************
 ***************]
	  	 Pending
 (Divisional of 6,218,371 B1
 C1039/7026)

  
 [*********************] 

													
	 WGS #

	  	 SN

	  	 FILING DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [**********]
	  	[**************]	  	 [******
 **]
	  	 [********]
 [*********]
 [*****]
	  	 [*******]
 [*******]
 [****]
	  	 [*******************
 ********************
 ********************
 ****]
	  	Pending
	 [************]
	  	 [***************]
 [***********]
	  	 [******
 **]
	  	 [********]
 [*********]
 [*****]
	  	 [*******]
 [*******]
 [****]
	  	 [*******************
 ********************
 ********************
 ****]
	  	 Pending
 Published 04/05/01

													
	 WGS #

	  	 SN

	  	 FILING 
 DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [*************
 **************
 *************]
	  	 [*****************]
 [***************]
 [*****************]
 [*************]
 [****************]
 [******************]
 [******************]
 [********************] [*********************]
	  	[********]	  	 [********]
 [*********]
 [*****]
	  	 [*******]
 [*******]
 [****]
	  	 [*******************
 ********************
 ********************
 ****]
	  	 Pending
 Pending
 Pending
 Pending
 Pending
 Pending
 Pending
 Pending
 Pending

  
 [***************] 
  

													
	 WGS #

	  	 SN

	  	 FILING
 DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [***********]
	  	[**************]	  	[********]	  	 [*********]
 [*****]
	  	 [****]
 [****]
	  	 [*******************
 ********************
 ******]
	  	Pending
							
	 [************]
	  	 [***************]
 [***********]
	  	[********]	  	 [*********]
 [*****]
	  	 [****]
 [****]
	  	 [*******************
 ********************
 ******]
	  	 Expired, Entered National Phase
 Published 12/02/99

							
	 [*************
 **************
 *************]
	  	 [*****************]
 [******************]
 [*************]
 [****************]
 [************]
 [*****************]
 [*****************]
 [*********************]
	  	[********]	  	 [*********]
 [*****]
	  	 [****]
 [****]
	  	 [********************
 *******************
 ******]
	  	 Pending
 Pending
 Pending
 Pending
 Pending
 Pending
 Pending
 Pending

  
 [************************************************] 
  

													
	 WGS #

	  	 SN

	  	 FILING DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [**********]
	  	[**************]	  	[********]	  	 [******]
 [********]
	  	 [*******]
 [*******]
	  	 [*******************
 ********************
 ********************
 ****************]
	  	Pending
							
	 [************]
	  	 [**************]
 [***********]
	  	[********]	  	 [******]
 [********]
	  	 [*******]
 [*******]
	  	 [*******************
 ********************
 *******************]
	  	 Entered National Stage
 Published 11/18/99

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

													
	 WGS #

	  	 SN

	  	 FILING
 DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [*************
 **************
 *************]
	  	 [*****************]
 [******************]
 [*************]
 [****************]
 [************]
 [*****************]
 [*****************]
 [*********************]
	  	[********]	  	 [******]
 [********]
	  	 [*******]
 [*******]
	  	 [*******************
 ********************
 *******************]
	  	 Pending
 Pending
 Pending
 Pending
 Pending
 Pending
 Issued August
29, 2001

  
 [***************************************************************************] 
  

													
	 WGS #

	  	 SN

	  	 FILING
 DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [**********]
	  	 [***************]
 [***********]
	  	[********]	  	 [******]
 [********]
 [****]
	  	 [*******]
 [*******]
 [*******]
	  	 [*******************
 ********************
 ********************
 ********************
 *******************]
	  	 National
 Filing/Pending
 PCT Published 07/30/98

							
	 [**********]
	  	 [***************]
 [******]
 [******]
 [*****]
	  	[********]	  	 [******]
 [********]
 [****]
	  	 [*******]
 [*******]
 [*******]
	  	 [********************
 *********************

*********************
 *********************
 ***************]
	  	 Pending
 Pending
 Pending
 Pending

  
 [*********************************] 
  

													
	 WGS #

	  	 SN

	  	 FILING
 DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [**********]
	  	[**************]	  	[********]	  	 [*****]
 [*****] [******]
 [**]
	  	 [****]
 [****]
 [*******]
 [****]
	  	 [*******************
 ********************
 ******************]
	  	 Issued
 US 6339,068

							
	 [************]
	  	 [***************]
 [***********]
	  	[********]	  	 [*****]
 [*****] [******]
 [**]
	  	 [****]
 [****]
 [*******]
 [****]
	  	 [*******************
 ********************
 ******************]
	  	Pending
							
	 [******]
 [******]
 [*********]
	  	 [*******]
 [***********]
 [***********]
	  	[********]	  	 [*****]
 [*****] [******]
 [**]
	  	 [****]
 [****]
 [*******]
 [****]
	  	 [*******************
 ********************
 ******************]
	  	Pending
							
	 [**********]
	  	[**************]	  	[********]	  	 [*****]
 [*****] [******]
 [**]
	  	 [****]
 [****]
 [*******]
 [****]
	  	 [*******************
 ********************
 ******************]
	  	 Pending
 CON of US
 09/082,649

  
 [*******************************] 
  

													
	 WGS #

	  	 SN

	  	 FILING
 DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [**********]
	  	[**************]	  	[********]	  	 [********]
 [********]
	  	[*******] [*******]	  	 [*******************
 ********************
 ********************
 *********]
	  	Abandoned in favor of C1037/7051
							
	 [**********]
	  	 	  	[********]	  	 [********]
 [********]
	  	[*******] [*******]	  	 [*******************
 ********************
 ********************
 *********]
	  	 Pending
 CON of US
 09/801,938

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 
  

 [***********] 
  

													
	 WGS #

	  	 SN

	  	 FILING
 DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [**********]
	  	[**************]	  	 [******
 **]
	  	 [***********
 ***]
	  	 [*********
 ***]
	  	 [*******************
 ********************
 ********************
 ********************
 ******]
	  	ABN in favor of C1037/7035WO designating US
							
	 [************]
	  	 	  	 [******
 **]
	  	 	  	 [*********
 ***]
	  	 [*******************
 ********************
 ********************
 ********************
 ******]
	  	Pending PCT

  
 [****************] 
  

													
	 WGS #

	  	 SN

	  	 FILING
 DATE

	  	 INVENTORS

	  	 ASSIGNEE

	  	 TITLE

	  	 STATUS

	 [**********]
	  	[**************]	  	 [******
 **]
	  	 [*******]
 [********]
	  	[*****]	  	 [*******************
 ********************
 ***********]
	  	Pending

  
  

 46 

  
 EXHIBIT D 

 
 Form of Press Release 
  
 NEWS RELEASE 
  
 Contact: 
  

			
	 Ted Hibben
	 	Karen L. Bergman or Michelle Corral
	Director, Business Development	 	BCC Partners (US)
	Coley Pharmaceutical Group	 	+1.650.575.1509
	+1.781.431.9000, ext. 1313	 	karenbergman@earthlink.net
	thibben@coleypharma.com	 	+1.415.794.8662
	 	 	 m_corral@yahoo.com

  
 For Immediate
Release 
  
 Coley Pharmaceutical Group Licenses
VaxImmuneTM Vaccine Adjuvant to Chiron

 Corporation for Inclusion in New Infectious Disease Vaccines 
  
 Wellesley, MA, December, XX, 2003 - Coley Pharmaceutical Group Inc. today announced
that Chiron Corporation has licensed Coley’s proprietary VaxImmuneTM vaccine adjuvant for incorporation into multiple vaccine candidates. 
  
 Under the terms of the agreement, Chiron receives a worldwide non-exclusive license to VaxImmuneTM, a powerful synthetic CpG vaccine adjuvant, for use in certain prophylactic infectious disease vaccine fields. Coley will receive upfront license fees
and development milestones. In addition, Coley will receive royalties from sales of products developed subject to the license. Further terms were not disclosed. 
  
 “This agreement with a leading vaccine developer further demonstrates the value of our CpG adjuvant technology to enhance the
performance of both prophylactic and therapeutic vaccines. I am delighted that Chiron has made VaxImmuneTM an essential component of their adjuvant strategy for the next generation of infectious disease vaccines,” said Robert L. Bratzler, Ph.D., President and CEO of Coley Pharmaceutical
Group. “Our collaboration with Chiron further advances our strategy to license Coley’s vaccine adjuvant technology for important 
  
 - more - 
  
 applications on a global basis, creating a new generation of highly effective vaccines.” 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. 

  
 About VaxImmuneTM 
  
 VaxImmuneTM is one member of Coley’s family of CpG TLR9 agonists, which are short synthetic DNA-like sequences that invoke
potent innate and adaptive immune responses of the body’s immune system, comprised of both antibody- and cell-mediated pathways. Recent published scientific research by independent researchers have demonstrated that VaxImmuneTM vaccine adjuvants are suitable for use in both
prophylactic and therapeutic vaccines and can elicit a powerful immune response against infectious disease and cancers. 
  
 Coley’s is actively seeking committed partners for the licensing and development of its VaxImmuneTM vaccine adjuvant products. In addition to the agreement announced today with Chiron,
Coley has previously signed two licenses for its vaccine adjuvants with GlaxoSmithKline for use in cancer vaccines and in infectious disease vaccines. 
  
 About Coley Pharmaceutical Group 
  
 Coley Pharmaceutical Group is developing several classes of highly specific, targeted immunoregulatory drugs with broad potential applications in cancers, asthma, allergy
and infectious diseases. Coley’s lead anti-cancer drug candidate, ProMuneTM, is being studied in Phase II trials for several different cancer indications; ActilonTM, Coley’s lead anti-viral drug candidate, is being developed for the treatment of Hepatitis C; and VaxImmuneTM, Coley’s lead vaccine adjuvant, is being clinically evaluated with partners in
vaccines for certain cancers and for Hepatitis B. Two other CPG compounds are being developed in collaboration with Aventis Pharmaceuticals for the treatment of asthma and allergic rhinitis. In addition to the Aventis partnership, Coley has two
license agreements with GlaxoSmithKline for the use of certain CpG TLR9 agonists in specified preventive and therapeutic infectious disease vaccines and certain therapeutic cancer vaccines. Coley has also received a $12 million DARPA award to
support the clinical development of Coley’s CpGs for the enhancement of anthrax vaccines. Coley is a private company with operations in the United States, Germany and Canada. For further information, please visit www.coleypharma.com.

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]